Gene expression pattern and functional analysis of CD8+ T cells from individuals with or without anti HIV/SIV noncytolytic activity by Aneela, Javed


 
 
 
 
Gene Expression Pattern and Functional Analysis of CD8+ T Cells from 
individuals with or without anti HIV/SIV noncytolytic activity. 
 
 
In partial fulfillment of the requirements for the degree 
“Doctor rerum naturalium (Dr. rer. nat.)” 
in the Molecular Medicine Study Program 
at the Georg-AugustUniversity Göttingen 
 
 
 
Submitted by 
Aneela Javed 
Born in Islamabad, Pakistan. 
 
 
 
Göttingen, May 2012 
 
 
 
 


 
 
 
 
 
 
 
 
 
 
 
 
With due respect to 
Prof. Dr. Wasim Ahmad 

 
 
 
 
 
 
 
 
 
 
 


 
Thesis Committee  
 
Supervisor  
PD Dr. SieghartSopper 
Flow Cytometry Unit 
Hämatologie und Onkologie, IHK 
Medizinische Universität Innsbruck 
ZVG 7-G5-009A 
Anichstr. 35 
A-6020 Innsbruck 
 
Co-supervisor 
Dr Ulrike Sauermann  
Deutsches Primatenzentrum 
Abteilung Infektionsmodelle 
Kellnerweg 4 
D-37077 Göttingen 
 
Second member of the thesis committee  
Prof. Dr. Holger Reichardt 
University of Göttingen Medical School (UMG) 
Dept. of Cellular and Molecular Immunology 
Humboldtallee 34  
D-37073 Göttingen 
 
Third member of the thesis committee  
Prof. Dr. Dieter Kube 
Georg-August-Universität Göttingen 
Abtl. Hämatologie und Onkologie 
Robert-Koch-Straße 40 
D-37075 Göttingen  
 


 
 
 
 
 
 
 
Affidavit  
 
I hereby declare that my doctoral thesis entitled “Gene Expression Pattern and Functional 
Analysis of CD8+ T Cells from individuals with or without anti HIV/SIV noncytolytic 
activity” has been written independently with no other aids or sources than those quoted. 
 
 
______________________________  
Aneela Javed 
 
May 2012 
Göttingen, Germany 
 
 
 
 
 
 
 
 


Related publications  
 
Within this thesis, the following publication has been submitted. 
• Rational design of HIV vaccines and microbicides: report of the EUROPRISE 
network annual conference 2011. Marie Borggren, Zelda Euler, Fabio Fiorino, 
KatrijnGrupping, David Hallengärd, Aneela Javed, Kevin Mendonca, Charlotte 
Pollard, David Reinhart, Nicolas Ruffin, Elisa Saba, Enas Sheik-Khalil, Annette Sköld 
Serena Ziglio, Robin Shattock, Gabriella Scarlatti, Frances Gotch,BrittaWahren. 
(Submitted, Journal of Translational Medicine).  
 
Parts of this thesis have been presented at international conferences. I want to thank all People 
who contributed to these studies.   
• Oral Presentation “Role of FAM26F in disease course of SIV infection” 
 EUROPRISE Network Annual Conference, Prague 14-17th November 2011. 
 
• Oral Presentation“Differential gene expression pattern of CD8+  T cells from 
individuals with and without anti HIV/SIV Noncytolytic activity” 
"Molecular Medicine" Annual PhD Retreat, September 2011. 
 
• Oral Presentation“Differential gene expression pattern of CD8+  T cells from 
individuals with and without anti HIV/SIV Noncytolytic activity” 
"Molecular Medicine" Annual PhD Retreat, September 2010. 
 
• Poster “Differential gene expression pattern of CD8+ T cells from individuals with and 
without anti HIV/SIV Noncytolytic activity”. 
4th international European congress of virology, Cernobbio Italy. 
 
 
 
 
 
 


Acknowledgment 
It would not have been possible to write this doctoral thesis without the help and support of 
the kind people around me, to only some of whom it is possible to give particular mention 
here. My cordial gratitude to my co-supervisor Dr. Ulrike Sauermann for her devoted 
guidance, resolute support and immense patience at all stages of this work. I would like to 
thank my supervisor Dr.Sieghart Sopper for his supervision and scientific guidance during my 
Ph.D study and research. I would like to thank my thesis committee members: Prof. Dr. 
Holger Reichardt and Prof. Dr. Dieter Kube for their time and insightful comments during our 
meetings. 
I want to acknowledge The Higher Education Commission of Pakistan for awarding me the 
scholarship for the completion of my doctoral studies. My earnest gratitude is reserved for 
Mr. Eugene Barsov SAIC-Frederick, USA for providing not only valuable materials for study 
but also for his guidance in cell line development. I would also like to thank Dr.  Christiane 
Stahl-Hennig, head of the unit of infection models, for the opportunity to complete my work 
within her group. 
I am very grateful to all my colleagues in the Units of Infection Models and Infection Biology 
for keeping enjoyable working atmosphere in the lab particularly Ann-Christin Schmädicke 
and Wiebke Ibing. My special thanks to Nicole Leuchte and Heidi Mayer for their technical 
assistance. 
Out of ordinary thanks to my friends Saadia Qamar, Misbah Touseef, Nayab Jütte and Dr. 
Humaira Naureen for their moral support and care that helped me to overcome setbacks and 
stay focused on my studies. Thanks for being there in difficult times. 
Where would I be without my family? My parents deserve special mention for their 
inseparable love, prayers and especially their confidence in me that has made even the darkest 
days bright. Special thank goes to my siblings for their love and encouragement. 
I would like to express my heart-felt gratitude to my fiancé Mr.Shams Abbasi and his family 
for their understanding and supportive attitude that has aided and encouraged me throughout 
this endeavor. Finally, I would like to thank everybody who was important to the successful 
realization of thesis, as well as expressing my apology that I could not mention personally one 
by one. 
A N E E L A  J A V E D 
 


Content  
I List of Figures..............................................................................................................X 
II List of Tables..............................................................................................................XII 
III List ofAbbreviations................................................................................................XIV 
IV Abstract...................................................................................................................XVII 
1 Introduction...............................................................................................1 
1.1 Origin and subtypes of HIV......................................................................................1 
1.2 Viral phenotypes.......................................................................................................2 
1.3 HIV-1 virionstructure................................................................................................2 
1.4 Genomic organization and gene products.................................................................3  
1.4.1 Structural proteins....................................................................................4 
1.4.2 Accessory proteins...................................................................................4 
1.5 Replication cycle of HIV-1.......................................................................................5 
1.6 Infection and disease.................................................................................................7 
1.7 Host immune responses against HIV-1 infection......................................................7 
1.7.1 Innate immunity.......................................................................................7 
1.7.1.1 Cellular HIV restriction factors...................................................8 
1.7.1.2 Dendritic cells..............................................................................9 
1.7.1.3 NK cells.....................................................................................10 
1.7.1.4 Interferons..................................................................................11 
1.7.2  Adaptive immunity................................................................................14 
1.7.2.1 Cellular responses......................................................................15 
1.7.2.2 CD8 T cell mediated Non cytotoxic antiviral response.............16 
1.7.2.3 Humoral responses.....................................................................19 
  1.8 Immune evasion of HIV...........................................................................................20 
  1.9 Non human primates models for HIVinfection........................................................20 
. 
2 Material and Methods.............................................................................22 
 
2.1       Material............................................................................................................22 
2.1.1       Laboratory equipment and consumables........................................................22 
2.1.2       Chemicals and Reagents.................................................................................23 
2.1.3       Reaction components and commercial kits....................................................25 
2.1.4       Antibodies used..............................................................................................25 
 
2.2 Methods............................................................................................................27 
 
2.2.1    Experimental animals........................................................................................27 
2.2.2 Preparation of virus stock..................................................................................27 
2.2.2.2 Virus titration............................................................................27 
2.2.2.3 Indirect immunoperoxidase assay.............................................28 
2.2.3  Preparation of peripheral blood mononuclear cells (PBMCs)..........................28 
2.2.4  Enrichment of specific cell types......................................................................29 


2.2.5  In vitro viral inhibition test................................................................................29 
            2.2.6  Viral RNA extraction and quantification..........................................................30 
2.2.7 Cellular RNA extraction....................................................................................31 
2.2.8   RNA isolation from blood.................................................................................32 
2.2.9   Primer designing and optimisation....................................................................32 
2.2.10  cDNA synthesis.................................................................................................33 
2.2.11 Real time quantification of cellular genes.........................................................33 
2.2.12  Flow cytometry..................................................................................................34 
2.2.13  Cloning and sequence analysis of FAM26F.....................................................34 
2.2.13.1 PCR amplification of FAM26F......................................34 
2.2.13.2 Extraction and purification of DNA from agarose gel...35 
2.2.13.3 Cloning...........................................................................35 
2.2.13.4 Purification of plasmid...................................................36 
2.2.13.5 BglII restriction digestion..............................................36 
2.2.13.6 DNA sequence analysis.................................................37 
2.2.14  In vitro stimulation of PBMCs with Interferons...............................................37 
2.2.15  T-Cell line development....................................................................................37 
2.2.15.1 Culturing of Packaging cell line GP2XTERT11............39 
2.2.15.2 Viral vector production..................................................39 
2.2.15.3  Activation of T Cells...................................................39 
2.2.15.4 Transduction...................................................................40 
2.2.15.5 Preparation of feeder cells..............................................40 
2.2.15.6 Post transduction cell culturing and sorting...................40 
 2.2.16 Statistical analysis.............................................................................................41 
 
3 Results.......................................................................................................42 
 
3.1 Characterization of CNAR+ and CNAR- animals.............................................42 
3.2 Microarray Expression Analysis.......................................................................45 
3.3 Quantitative PCR analysis of selected differentially expressed genes……......48 
3.4 Comparison between CNAR+ and CNAR- animals..........................................49 
3.5 Comparison between SIV-infected and non-infected animals..........................54 
3.6 Genetic Studies of FAM26F..............................................................................56 
3.7 FAM26F regulation during course of infection.................................................57 
3.7.1 Gene expression variations after infection............................................59 
3.7.2 Correlation of gene expression with viral load......................................62 
3.7.3 FAM26F – an early predictor of viral load............................................63 
3.8  FAM26F regulation during course of immunization.........................................65 
3.9  FAM26F Correlation with Other Immune Components...................................74 
3.10  Expression of FAM26F in different lymphocyte populations…......................75 
3.11  In Vitro Activation Studies of FAM26F...........................................................76 
3.12  Establishment of Permanent Monkey CD8+ T cell Line..................................78 
 3.12.1 Principle.............................................................................. ..................78 
3.12.2 Vector Stock Preparation and Titer Determination...............................79 
3.12.3 Activation of Target Primary T Cells....................................................80 


3.12.4 Transduction of Target Primary T-Cells................................................82 
    3.12.5 Post Transduction Culturing.................................................................83 
    3.12.6 FACS analysis of CD4 Cell Line.........................................................85 
 
4 Discussion.................................................................................................87 
 
4.1 Difference between CD8+ T cells from infected and noninfected animals...…89 
4.2 FAM26F expression after interferon stimulation..............................................89 
4.3 FAM26F expression upon infection..................................................................90 
4.4 FAM26F expression upon immunization........................................................91 
4.5 phenotypic characterization of CD4 cell line....................................................96 
6 Summary and conclusion......................................................................99 
7 References..............................................................................................102 
8 Appendix................................................................................................118 
9 Curriculum Vitae..................................................................................123 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


List of Figures  
Figure 1.1 The HIV viral structure ......................................................................................3 
Figure 1.2 HIV-1 genome organizations..............................................................................4 
Figure 1.3 HIV-1 replication cycles ....................................................................................6 
Figure 1.4 Type I signaling pathway..................................................................................12 
Figure 1.5 Activation of cellular and humoral responses................................................15 
Figure 2.1 A schematic representation of in vitro viral inhibition test...............................30 
Figure 2.2 Schematic representations of steps leading to conversion of primary cells  
into cell-line...................................................................................................38 
Figure 3.1 Flow cytometricdot plot to determine thepurityof aMACS-separated cell 
populationA) degree of purity of CD8+ T cells; B) CD4+ T 
cellsfromPBMCs.............................................................................................. 43 
Figure 3.2 Fold suppression of SIV replication by CD8+ cells from CNAR+ and CNAR-
animals from SIV-infected and non-infected monkeys................................... 45 
Figure 3.3 Viral load of CNAR+ and CNAR-long term non progressors over a period of 
189wpi.............................................................................................................45
Figure 3.4 Heat Map of the microarrays performed with the CD8+ T cells for the 
comparison of (A) SIV+vs SIV- samples (B) CNAR+vs CNAR-
samples..............................................................................................................47 
Figure 3.5 Biological processes as defined by the Gene Ontology consortium for 
significantly changed genes..............................................................................48 
Figure 3.6 Fold difference in mRNA expression of selected genes in (A) SIV-infected (B) 
non-infected CNAR- animals as compared to CNAR+ animals.......................50 
Figure 3.6C Relative gene expression of FAM26F, CST6 and TNFSF-13B in CD8+T cells 
from the SIV-infected and non-
infectedanimals......................................................................................................
......51 
Figure 3.7A Fold difference in mRNA expression of Con-A stimulated CD8+ T cells from 
CNAR- animals as compared to CNAR+ animals in both SIV-infected and non-
infected groups..................................................................................................52 
Figure 3.7B Relative gene expression of FAM26F in CD8+ T cells from CNAR+ and 
CNAR- animals before and after co-cultivation with SIV-infected CD4+ T 
cells....................................................................................................................53 
Figure 3.8 Fold difference in the expression of genes in un-stimulated CD8+ T cells from 
CNAR+ and CNAR- animals in SIV-infected and non-infected animals….….53 
Figure 3.9A Fold difference in gene expression of non-infected animals as compared to the 
SIV-infected animals……………………………………………………….…54 
Figure3.9B Genes that were found to be significantly differentially expressed in SIV-
infected animals as compared to non-infected animals……………..……..….55 


Figure 3.10 Electropherogram of ethidium bromide stained 1% agarose gel showing PCR 
amplified FAM26FcDNA products in 12 selected animals..............................56 
Figure 3.11 FAM26F Consensus Sequence alignments with the GenbankFAM26F sequence 
Figure 3.12 ∆CT of FAM26F relative to GAPDH plotted against log viral load………….57 
Figure 3.13 Time lines for the (A) Experiment 1 (B) Experiment 2 indicating the time 
points when blood samples were taken for quantification of specified genes...59 
Figure 3.14 Expression variations of (A) MX1 (B) IP-10 (C) Tetherin (D) FAM26F during 
course of SIV infection in two independent experiments............................60-61 
Figure 3.15 Correlation of (A)  MX1 (B) IP-10 (C) tetherin (D) FAM26F gene expression 
levels (∆ CT) with viral load at week 24 post infection....................................63 
Figure 3.16 Significant correlation of 2wpi FAM26F expression with (A) viral load 2wpi 
(B) viral load 12wpi (C) viral load 24wpi.........................................................64 
Figure 3.17 Correlation of pre infection expression of FAM26F with viral load 2, 12 and 
24wpi in (A) experiment (B) experiment..........................................................65 
Figure 3.18 Expression variations of (A) MX1 (B) IP-10 (C) tetherin (4) FAM26F during course 
of immunization in two vaccine experiments....................................................67-70 
Figure 3.19 Significant differences between group 1 (GP1) and group 2 (GP2) after 
immunization................................................................................................71-72 
Figure 3.20A Viral Load of three infected groups over time..................................................73 
Figure 3.20B Fraction of uninfected animals in controls and both vaccine groups during the 
course of challenge............................................................................................73 
Figure 3.21 Correlation of FAM26F with (A) MX1 (B) IP-10 and (C) tetherin RNA levels 
in PBMCs from two independent vaccine experiments………………….….. 75 
Figure 3.22 Expression of FAM26F in different cell types.................................................76 
Figure 3.23 Changes in the expression pattern of selected genes after 100ng of INF-α, INF-
γ and TNF-stimulation……………………………………………….……77-79 
Figure 3.24 GFP transfected GP2xTERT11 producer cell line (A) 24 hours post 
transfection (B) 36 hours post transfection…………....................................…79 
Figure 3.25 FACS analysis of C8166 cells (A) non-transduced C8166 cells as negative 
control (2B) C8166 cells transduced with undiluted viral vector stock………80 
Figure 3.26 Percentage of live/dead cells, after 48 hours activation of PBMC activation 
with (A) plate bound anti CD3 antibody (B)Concanavalin-A……………...81 
Figure 3.26 Percentage ofCD69-HLADR double positive cells on CD4+ cells (C) CD8+ 
cells (D) after Concanavalin-stimulation………….…………………………..82 
Figure 3.26 Percentage ofCD69-HLA-DR double positive cells on CD4+ and (E) CD8+ cells 
(F) after plate bound anti CD3 antibody 
stimulation…………………………………………………………………….82 
Figure 3.27 FACS histograms of transduced LNGFR+ (A) C8166 positive control of 
transduction (B) Target primary CD4+T cells (C) Target primary CD8+ T 
cells……………………………………………………………………...…….82 


Figure 3.28 FACS dot plots of CD8+ T cells showing percentages of  LNGFR+ cells in (A) 
controls (B) Transduced d1 (C) d3 of culture (D) d6 of culture (E) d9 of culture 
………………………………………………………………………………..84 
Figure 3.29 FACS chromatograms of CD4+ T cell line showing expression of different cell 
surface markers……………………………………………………………85-86 
Figure 4.1 Graphic representation of probability of FAM26F transmembrane sequence 
motifs in (A) Homo sapiens (B) Macaca mulatta………………………….....93 
Figure 4.2 Sequence alignment of human, monkey and mouse FAM26F………………..94 
Figure 4.3 A hypothetical model for the mode of action of FAM26F…………………....97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
List of Tables  
 
Table 1.1:Type I and Type II Interferon induced genes/responses.........................................13 
Table 1.2: Proteins that have antiviral effect but lack identity to the CD8+ T cell antiviral 
  factor (CAF)......................................................................................................18 
Table 2.1: General laboratory equipments and consumables...................................................22 
Table 2.2: Chemicals and Reagents........................................................................................23 
Table 2.3: Reaction components and commercial kits.............................................................25 
Table 2.4: List of Antibodies...................................................................................................25 
Table 2.5: Reaction components and their respective concentration for cDNA synthesis…..31 
Table 2.6: Reaction components and their concentrations for PCR........................................35 
Table 3.1: Animal grouping on the basis of viral inhibition test………………….................44 
Table 3.2:Alleles identified after sequencing of FAM26FcDNA clones from selected CNAR+ 
and CNAR- animals. .......................................................................................57  
Table App 1:Table briefly summarizing the possible function/s of genes selected for 
validation…………………………………………………………………………................120 
Table App 2:Table depicting accession number of the genes validated by qRT PCR along 
with primer sequences used for amplification on along with amplicon lengths……….........122 
 
 
 
 
 
 
 
 
 
 
 


 
III    List of Abbreviations  
 
Abbreviation  Explanation  
°    Degree  
Amp   Ampicillin  
Bp   Base pair(s)  
C   Celsius  
CD   Cluster of differentiation  
cDNA   Complementary DNA  
CNAR   CD8+ T cell noncytolytic antiviral response 
CO
 2   Carbon dioxide  
CXC   Cystein X cystein 
d   Day(s)  
DMEM  Dulbecco’s modified eagle medium  
DMSO  Dimethyl sulphoxide 
DNA   Deoxyribonucleic acid  
DNase I  DNA-hydrolyzing enzyme  
dNTP   Deoxynucleotide triphosphate  
PBS    phosphate buffered saline  
Dpi   Days post infection  
dsDNA  Double stranded DNA  
E.coli   Escherichia coli  
EDTA   Ethylenediaminetetraacetic acid  
env   Retroviral envelope protein  
FCS   Fetal calf serum  
FSC   Forward scatter  


FACS   Fluorescence activated cell sorting 
GAPDH  Glyceraldehyde-3-phosphate dehydrogenase  
gDNA   Genomic deoxyribonucleic acid  
h   Hour(s)  
H2O   Water 
IFN   Interferon 
Kb   Kilo base pairs  
kDa   Kilo Dalton  
LB   Lysogeny broth   
LTR   Long terminal repeat  
mAb   Monoclonal antibody  
min   Minute  
mRNA  Messenger RNA  
NCBI   National Centre for Biotechnology Information  
ORF   Open-reading frame  
PAGE   Polyacrylamide gel electrophoresis   
PBS   Phosphate-buffered saline  
PCR   Polymerase chain reaction  
pH   Potentiahydrogenii 
PK   Proteinase K  
qPCR   Quantitative PCR  
RNA   Ribonucleic acid  
RNase   RNA-hydrolyzing enzyme  
RT   Room temperature (21°C)  
RT   Reverse transcriptase  
Rpm   Revolutions per minute 
ssDNA  Single stranded DNA  


TCID50  Tissue culture infectious dose 50% 
U   Unit  
VSV-G  Vesicular stomatitis virus G protein  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


ABSTRACT 
CD8+ T cell mediated antiviral response (CNAR) is associated with long-term control of HIV-
infection and attributed to the secretion of an unknown factor called soluble CD8+ cell 
antiviral factor (CAF). In order to identify CAF, microarray data from CD8+ cells displaying 
high CNAR activity and CD8+ cells that lack CNAR were analyzed. Out of more than 50 
differentially regulated genes, differential expression of 16 genes was validated by qRT-PCR 
in CD8 cells from 21 monkeys. FAM26F was identified as a sole candidate that was 
significantly differentially expressed in samples from SIV-infected as well as non-infected 
animals. FAM26F expression increased in CNAR- CD8+ T cells during their co-cultivation 
with SIV-infected CD4+ T cells in viral inhibition test. FAM26F was found to be expressed 
on three major blood cell populations (CD4+, CD8+ T cells and B cells). In vitro stimulation 
studies revealed that FAM26F expression was greatly induced in PBMCs after 6hrs of IFN-γ 
stimulation, and to some extent by IFN-α. Next, the expression pattern of FAM26F before and 
after infection was investigated in two independent AIDS vaccine experiments comprising in 
total 42 monkeys. In both experiments, FAM26F expression along with other innate immune 
modulators was significantly increased in PBMCs and followed same in vivo expression 
pattern after infection as Mx1, IP-10 and tetherin after SIV-infection. Its expression was also 
found to be significantly correlated with Mx1, IP-10 and tetherin. In first experiment, 
preinfection RNA levels of FAM26F were inversely correlated with 2, 12 and 24 wpi viral 
load while in other experiment, 2wpi expression of FAM26F was positively correlated with 
plasma viral RNA copies at 12, 24 and 48 wpi. Expression of FAM26F, MX1, IP-10 and 
tetherin was studied before and after immunization in two groups of animals that were finally 
boosted with fowlpox virus- or adenovirus-derived vector respectively. Increased level of 
protection in adenovirus-derived vector group was most likely attributed to significantly 
elevated expression of IP-10 (24hrs post boosting), FAM26F and tetherin (24 hrs and 48hrs 
post boosting) indicating more pronounced IFN-γ responses or a unique balance between type 
I and type II responses. In summary, the results emphasize that FAM26F may be an important 
regulator of innate or adaptive immune response. FAM26F expression may be an early 
prognostic marker for SIV/HIV infection. Lower expression of FAM26F before infection may 
indicate an immune status that is able to limit early viral replication, whereas a strong increase 
after infection may indicate an early immune dysregulation that is later on associated with 
higher viral load. Irrespective whether FAM26F is involved directly in regulation of viral 
replication or indirectly via the immune defense; our study has shown that it is an important 
molecule that clearly merits further investigation. 

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 Introduction  
More than three decades have passed since the first case of an acquired immunodeficiency 
syndrome (AIDS) [1, 2] and isolation of its causative agent human immunodeficiency virus 
(HIV) from the lymph node of the infected patient [3]. After its worldwide dissemination, 
infecting more than 33.4 million people (AIDS Epidemic Update, UNAIDS, WHO, as of 
December 2007) HIV is one of the most catastrophic examples of emergence, transmission 
and propagation of microbial genome [4]. 
HIV belongs to the genus of lentiviridiae of the retroviridae family. Lentiviridiae comprise of 
five groups each restricted to a single mammalian family namely ovines-caprines (CAEV), 
bovines (BIV), felines (FIV), equines (EIAV) and primates including SIVs, HIV-1 and HIV-
2. Lentiviruses are host-specific enveloped RNA viruses, characterized by a long latency 
period rendering slow onset of disease [5]. They complicate the development of an effective 
immune response of the host due to their high mutation rate and variability[6] 
1.1- Origin and subtypes 
On the basis of genetic differences, geographical distribution and pathogenesis, HIV can be 
divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). Although the 
origin of HIV is disputed, evidences based on the identical genomic organization led to the 
conclusion that HIV originally came from SIV (simian immunodeficiency viruses) infecting 
non-human primates. HIV-1 is closely related to SIVcpz, simian immuno deficiency virus 
infecting chimpanzees [7] while HIV-2 originated from SIV in sooty mangabeys (SIVsm) [8]. 
Furthermore HIV-1 groups M and N are thought to be originated in SIVcpz from Gabon [9] 
and that group O originated in gorillas [10]. It is important to note that SIVcpzand SIVsm  do 
not cause disease in their natural hosts but induces in other monkeys like Asian macaques, an 
AIDSlike disease similar to humans [11]. It is considered that most likely the virus has 
entered the human population through zoonotic or cross-species transmission from non-
human primates [12][13] 
So far four groups of HIV-1 namely M (major), O (Outlier), N (non-M, non-O) and P (closer 
to SIVgor) [14] have been identified on the basis of genomic analysis of viral sequences from 
both env and gag genes [15]. Group 'M' is the cause of 90% of HIV/AIDS cases and is further 
subdivided into 11 clades (A through K) [16-19]. Simultaneous infection and recombination 
between different subtypes gives rise to "circulating recombinant forms" orCRFs. These 


subtypes have distinct geographic distribution. The most prevalent are subtypes B (found 
mainly in North America and Europe), A and D (found mainly in Africa), and C (found 
mainly in Africa and Asia) (HIV sequence compendium 2008). HIV-2 is geographically more 
restricted [20], less transmissible [21] and less pathogenic [20]. It is most prevalent in Africa 
and has 8 known HIV-2 groups (A to H) but only group A and B are prevalent. 
1.2- Viral phenotypes 
HIV can infect the immune cells such as helper T cells (specifically CD4+ T cells) [22] 
macrophages [23] and dendritic cells. After binding to CD4 (main receptor) on these target 
cells, HIV uses secondary transmembrane G protein-coupled chemokine receptors, mainly 
CCR5 and CXCR4 as co-receptors for attachment and subsequent entry into cells [24]. 
Macrophage tropic (M-tropic) strains of HIV-1 (R5) use β-chemokine receptor CCR5 for 
entry [25]. They are non-syncytia-inducing strains and replicate in vitro slower than the T-
tropic or syncytia-inducing (SI) strains which use α-chemokine receptor, CXCR4, for entry 
[26]. 
Generally, during acute virus infection, R5 virus emerges as the dominant type. People 
homozygous with the CCR5-∆32 deletion are therefore resistant to infection with R5 virus 
and this homozygosity appears to account for resistance of some multiply-exposed individuals 
to HIV-1 infection [27]. The reasons for the selective transmission of R5 viruses are still 
unclear. Over time, in many cases, HIV becomes dual/tropic (that can use both receptors 
R5/X4) [28] or X4 strain emerge at a later stage causing more rapid progression to AIDS [29].  
1.3- HIV-1 virion structure 
The viral particle, with a diameter of about 110 nm, has a cone-shaped core composed of 
almost 2000 copies of p24 viral protein. Inside the capsid are two identical (9.2 kb each) 
single stranded RNA molecules, found to be closely associated with viral reverse transcriptase 
(RT) the enzymes integrase and protease and the nucleocapsid proteins P7 and p9 [30]. Viral 
capsid is surrounded by a layer called the matrix made up of protein p17.Surrounding the 
matrix is the viral envelope that is composed of two layers of phospholipids taken from the 
membrane of a human cell when a newly formed virus particle buds from the cell The 
envelope also contains cellular proteins acquired during virus budding, including ICAM 
(intracellular adhesion molecule), β 2-microglobulin and the human major histocompatibility 
	
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complex (MHC) class I and II molecules [31]. Embedded in the viral envelope are 72 spikes 
[32]. Each spike consists of three molecules of external surface envelope protein, gp120, 
(CAP) interacting non-covalently with three molecules of transmembrane protein, gp41, 
(stem) that crosses the lipid bilayer to anchor the structure into the viral envelope. This 
glycoprotein complex is essential for attachment and fusion of virus with target cells. Both 
these surface proteins, especially gp120, have been considered as targets of future treatments 
or vaccines [33]. 
 
Fig 1.1: The HIV viral structure. HIV virus structure depicting important structural 
components. p: Protein; gp: Glycoprotein. Adapted from: Thomas K. Kuby.“Immunology.” 
 
1.4- Genomic organization and gene products 
The RNA genome of HIV consists of at least seven structural landmarks (LTR, TAR, RRE, 
PE, SLIP, CRS, and INS), nine genes (gag, pol, and env, tat, rev, nef, vif, vpr, vpu, (or vpx in 
the case of HIV-2), sometimes a tenth tev, (a fusion of tat, env and rev) and 19 encoded 
proteins.The coding regions of each strand of HIV RNA are flanked by long terminal repeat 
(LTR) composed of in total three elements with regulatory functions, R- and U5 region at the 
5´end and U3 and R at the 3´end. The LTRs are duplicated upon intergration of the virus. PE 
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(Psi element) is involved in viral genome packaging and recognized by Gag and Rev proteins 
while the SLIP element (TTTTTT) is involved in the frame shift in the Gag-Pol reading frame 
required to make functional Pol. (HIV Sequence Compendium 2008 Introduction) 
 
 
Fig 1.2: Depiction of the ~10 Kb HIV-1 genome showing the organization of its genes. 
Modified from Costin Virology Journal 2007. 
 
1.4.1-Structural proteins 
HIV genome contains three important genes to make the structural proteins for new virus 
particles. 
1. The gag gene encodes the precursor p55 (polyprotein) which is further cleaved by the viral 
protease to the structural proteins; the matrix, the capsid, and the nucleocapsid protein (p24, 
p17, p7 and p6) [34]. 
2. The pol gene codes for a precursor protein which, after proteolytic clevage, results in three 
viral enzymes: p11 protease, p66/51 RT, and p32 integrase. These proteins are vital to virus 
replication [34] 
3. The env gene codes for the precursor gp160 which is later proteolytically cleaved into two 
envelope proteins gp120 and gp41 that are crucial for the virus to bind and enter a host cell 
[32] 
1.4.2-Accessory proteins 
In addition to these genes, the HIV-1 genome encodes accessory proteins with important 
functions for viral replication and infection.The tat gene composed to two exons encodes Tat 
protein that acts as transcriptional trans-activator for TAR (Tat responsive region) elements 
located in the LTR to initiate viral mRNA transcription and promote viral RNA elongation. 
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The Rev protein (p19 regulator of viral expression) is involved in shuttling the RNAs from the 
nucleus and the cytoplasm by binding to RRE (Rev responsive element) located in the env 
gene. This interaction permits un-spliced mRNA to enter the cytoplasm from the nucleus and 
to give rise to full-length viral proteins needed for progeny production [35]. The Nef protein 
(p27) is one of the first and most immunogenic HIV proteins to be produced in infected cells 
and modulates diverse properties to increase the virion infectivity. It down-regulates CD4 [36] 
as well as the MHC class I and class II molecules [37]. It also induces complex changes in 
cellular trafficking, antigen presentation, and signal transduction [38]. Furthermore, Nef may 
also deregulate the communication between T cells and antigen-presenting cells [39]. In 
conclusion multiple Nef activities cooperate to delay the elimination of HIV-1-infected cells 
by the immune system and make the cellular environment more conducive for viral spread. 
Vif, Vpu, and Vpr, all seem to target antiviral factors for ubiquitin-dependent proteasomal 
degradation to make the intracellular environment more conducive for viral replication. The 
Virion infectivity factor (Vif, p23) seems to be important for the cell-cell transmission of 
virus and prevents the action of viral restriction factor APOBEC3G. It has been reported to be 
crucial for proviral DNA synthesis and involved in the final stages of the nucleoprotein core 
packing [40][41]. 14 kDa  viral protein R (Vpr) is involved in activation of proviral 
transcription, cell-cycle arrest in the G2 phase, induction of cell death, and enhancement of 
reverse transcription [42-44]. HIV-1 viral protein U (Vpu) is a 16 kDa protein with two main 
functions. On one hand it recruits ligase complex to newly synthesized CD4 in the 
endoplasmic reticulum for its proteasomal degradation [45, 46]. Thus facilitates the virus 
release, averts super infection, and enhances the incorporation of functional Env proteins into 
progeny virions. On other hand it antagonizes the cellular restriction factor tetherin [46]. 
 
1.5- Replication cycle 
HIV replication cycle starts with the high-affinity attachment of the CD4 binding domains of 
gp120 (V3 loop)[47] to the CD4 [48] receptor causing conformational changes in the viral 
protein gp120 and exposure of co receptor (CCR5/CXCR4) binding sites [49]. This more 
stable two-pronged attachment results in fusion of the membranes and subsequent injection of 
the viral genome and other enzymes, including reverse transcriptase- (the ribonuclease a 
subunit of the RT) integrase, and proteaseinto the cell. After entry, viral RNA is reverse 
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transcribed in cDNA and integrated into the genome of host by the viral integrase. To actively 
produce the virus, certain cellular transcription factors like NF-κB are needed [50]. When the 
host cell is activated, cellular RNA polymerase transcribes the viral DNA. Multiply-spliced 
mRNAs are transcribed and produce the regulatory proteins Tat, Rev and Nef. Transcription 
and elongation is increased by Tat activity on the TAR in the LTR region while an increase in 
the level of Rev accelerates the cellular translocation of unspliced viral RNA. Nef makes up 
to 80% of the early viral transcripts. Expression of late transcripts gives rise to structural 
proteins Gag and Env. During the post-translation period, the envelope proteins are 
glycosylated and cleaved by cellular proteases into gp120 and gp41. The envelope proteins, 
Gag polyproteins, Pol polyproteins and the new viral genomes are assembled into new viral 
particles at the cell membrane. The virus progeny particles are released by budding through 
the cell membrane. The maturation of the virus particles is completed during and after 
budding from the host cell when the viral protease cleaves the Gag and Pol polyproteins into 
functional proteins.  
 
 
Fig 1.3: Different steps in HIV replication cycle including attachment, entry, reverse 
transcription, integration, virion formation and budding. (Adapted from Eric M Poeschla. 
http://mayoresearch.mayo.edu/mayo/research/poeschla/images/hiv_1.gif) 
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1.6- Infection and disease 
HIV infection generally evolves into three phases namely acute infection (primary infection), 
latency period or chronic infection and finally AIDS leading to death. The acute phase is 
characterized by rapid viral replication with a burst in plasma viremia allowing systemic 
dissemination of the virus and may last 1 to 3 months [51][52]. Symptoms include fever, 
pharyngitis(sore throat), rash, myalgia(muscle pain). Generally, with the onset of humoral and 
cellular immune response the plasma viremia drops to an individual set point [53]. This stage 
of HIV infection can vary between two to 20 years.  A small percentage of infected 
individuals are rapid progressors while 80% are “normal” progressors in whom survival time 
is eight to ten years without antiretroviral treatment [37]. Approximately 5-8% of all HIV-
infected people fall into the group of long-term non progressors (LTNPs). These individual 
remain infected for > 10 years without showing signs of the disease and without therapy [54]. 
A subgroup called elite controllers are those LTNPs with viral RNA copies <50/ml plasma 
although they have been infected for 2 to >10 years [55] . When infected individuals progress 
to AIDS, CD4+ cells number drops below 200 cells/µl leading to the loss of cell-mediated 
immunity and thus an increase in  plasma viremia [37] and opportunistic infections and 
ultimately, the death of the patient [56] 
1.7- The host immune responses against HIV-1 infection 
AIDS is essentially an infection of the immune system. An early effective host immune 
system is crucial to control against HIV infection. Two major defense pathways are described 
within the host immune system: innate and adaptive immunity.  
1.7.1 Innate immunity 
Apart from physical barriers (mucus, low pH, and epithelial integrity), a number of secreted 
cationic peptides and small secreted proteins at the mucosal surfaces can modulate HIV 
infection. A small cationic peptide SEVI (semen derived enhancer of virus infection) 
enhances in vitro HIV infection through formation of amyloid fibrils that capture and focus 
virus onto target cells. Small cationic peptides produced by mucosal epithelial cells called 
defensins, contribute to anti-HIV by several mechanisms including impairment of gp120 
binding to CD4 [57], induction of β-chemokines [58], inhibition of the fusion step [59]. They 
also act as chemo-attractants for T cells, monocytes and dendritic cells (DCs) and regulate 
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cellular activation and cytokine production [60]. Although local elevations in α-defensin 
levels during genital tract infections leads to enhanced HIV acquisition [60], it is not clear 
either pro- or anti-HIV activities of defensins predominate in vivo.  
Among the solublecomponents of the innate immune system with anti-HIV activity are the 
complementsystem and mannose-binding lectins(MBL). These soluble products bind to HIV 
and either lyse thevirus directly or induce macrophages to phagocytose the virus [61, 62]. 
TheCC chemokines (RANTES, MIP-1α and MIP-1β may also block HIV access to the 
CCR5co-receptors [63], and are able to attract the entire immunological repertoire ofcells (T 
and B cells, DC and macrophage) to the mucosal site.  
Two of the 18 human whey acidic proteins family members are documented for their anti HIV 
activity. Secretory leukocyte protease inhibitor (SLPI) found in saliva elicit its anti HIV 
activity by binding to annexin II (an enhancer of HIV entry) and thus may contribute to the 
infrequent oral transmission of HIV[64-66]. Elafin, with unknown underlying mechanism is 
over-expressed in female genital tract [66]. However another member of same family 
WFDC1/ps20 (whey acidic protein four-disulphide core domain 1) can enhance HIV infection 
[67]. 
A high concentration of stromal-derived factor (SDF1), a ligand of the CXCR4 receptor is 
expressed in human cervico-vaginal and rectal epithelial cells can preventthe transmission of 
X4-viruses across mucosal surfaces [68]. 
 
1.7.1.1 Cellular HIV restriction factors 
Intrinsic retroviral restriction factors such as apolipoprotein B editing complex 
(APOBEC)3G/F, tripartite motif (TRIM)5α [69]and tetherin [70] are reported to display broad 
antiviral effects.  
APOBEC3G is incorporated into HIV-1 virions and catalyses the deamination of cytidine to 
uridine during negative-strand DNA synthesis [71, 72]. These hypermutations can lead to the 
degradation of the viral DNA and/or become fixed as G-to-A changing TGG (W) to 
TAA/TAG (stop) codons. In both cases the virus is inactivated [72]. To counter the effect of 
APOBEC3G, virion infectivity factor (Vif) serves as an adaptor molecule to link a cullin 5-
based E3 ubiquitin ligase complex to APOBEC3G thus inducing its polyubiquitination and 
subsequent proteasomal degradation, thereby preventing its packaging into budding 
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virions.[73] Vif also mediates the degradation of APOBEC3F, which is another potent 
inhibitor of HIV-1. 
TRIM5α (tripartite motif 5-a) represents a host restriction factor that displays species-specific 
retrovirus restriction. While for instance rhesus TRIM5α can restrict HIV-1 and some SIVsm 
strains, human TRIM5α cannot restrict HIV-1 but HIV-2. The species specific differences are 
based on the presence of a target sequence in the viral capsid proteins as well as on species-
specific differences in the C-terminal region of TRIM5α. TRIM5a proteins can interact with 
incoming capsid protein and may induce rapid uncoating by proteasomal degradation [74, 75] 
Tetherin is a type II single-pass transmembrane protein that inhibits the release of viral 
particles [70]. It contains a cytoplasmic N-terminal region, followed by a transmembrane 
(TM) domain, a coiled-coil extra-cellular domain, and a C-terminal glycophosphatidylinositol 
(GPI) anchor [76]. After dimerization by three cysteine residues, it directly tethers the nascent 
virions to the surface of the producer cells with one membrane anchor sticking in the virion 
and the other in the cell. VPU interacts with TM domain of tetherin and recruits it to Trans 
Golgi network or early endosomes for its proteasomal and/ or lysosomal degradation [77]. 
1.7.1.2 Dendritic cells  
Dendritic cells (DCs) play a pivotal role in the initiation and regulation of immunity. They are 
derived from hematopoietic bone marrow progenitor cells. DCs represent a heterogenous cell 
population depending on their differentiation status and their anatomical location. There are 
two main types of DCs (1) plasmacytoid dendritic cells (pDC) and (2) conventional dendritic 
cells (cDC) that differ markedly in their developmental program and function.  
Pre-cDC precursors migrate to the lymphoid organs to convert into cDC[78]. cDC express 
TLR2 and TLR4 and play an essential role in antigen presentation in vivo [79]. In contrast, 
pDC develop fully in the bone marrow and disseminate through the blood [80]. They express 
TLR7/8 and TLR9. The main functional feature of pDC is their ability to quickly secrete large 
amounts of type I IFN (predominantly INF-α) in response to viral products [81], but their 
antigen-presenting function in vivo remains unknown [82] 
pDC recognize HIV ss RNA via TLR7 receptors leading to subsequent upregulation of MHC 
and costimulatory molecules production of high levels of type 1 IFNs[61].The earliest 
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systemic cytokine elevations produced by pDCs in acute HIV infections include rapid but 
transient increase in IFN-a and interleukin (IL)-15 levels in plasma [83]. This is followed by 
initiation of a rapid but more sustained increase in TNF-α and IP-10 while slightly slower but 
more sustained increase in IL-18 by cDCs response [84]. 
A positive correlation betweenblood IPC (interferon producing cells) number, IFN-α 
production, and clinical state of HIV-infected subjects is well established. High viral load and 
a progressive disease in HIV individuals have beensuggested to have a close correlation with 
a decreased number of pDCs in peripheral blood. Furthermore the ability of pDC to produce 
INF α during acute HIV infection is impaired [85]. While IFN-α has antiviral effects, it should 
be noted that chronic long term INF-α production could be deleterious as it induces abnormal 
immune activation potentially leading to HIV pathology [86]. Relatively swift resolution of 
interferon responses in HIV controllers compared to progressors (as evident from ISG 
expression pattern in whole genome transcript studies [87] and lack of chronic immune 
activation in non-pathogenic SIV infections (in sooty mangabeys and African green monkeys) 
as compared to persistent immune activation in pathogenic SIV infection (e.g. rhesus 
macaques) [88-90] emphasize that achieving the optimal IFN response by pDC, limiting the 
IFN dependent immunopathology is the main discriminatory factor between pathogenic and 
non-pathogenic infections and still to be resolved. 
Dendritic cells display another adverse role in HIV-infection as they cancapture and 
internalize virions via DC-SIGN (lectin dendritic cell-specific, intercellular adhesion 
molecule-grabbing non-integrin) leading to rapid dissemination of HIV [91][92].  
 
1.7.1.3 NK cells 
In addition to pDCs, HIV infection can rapidly activate NK cells predominantly driven by IL-
15 and IFN-α secreted by dendritic cells and monocytes. Impairment of NK cell function with 
persisting viral replication and disease progression is characterized by decrease in CD56high 
(regulatory) NK cells (in part due to their recruitment to lymph nodes) and accumulation of 
CD56low (anergic effector) NK cells [93] 
NK cells represent a highly heterogenic cell population characterized by differential 
combination of activating and inhibitory KIRs in conjunction with their HLA class I ligands. 
These unique combinations not only dictate the functionality of NK cells but also effect their 
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differential expansion [94]. As an example, co-expression of HLA-Bw480I and KIR3DS1 has 
been found to be associated with low-level viremia and delayed disease progression in early 
HIV-infection [95]. The presence of KIR3DL has been associated with decreased NK cell 
frequency and high viral load in SIV-infected rhesus monkeys [96]. Furthermore, a SNP 
associated with elevated HLA-C (ligand for receptors of the KIR2DL and KIR2DS family) 
expression is also associated with lower viral set point and slower disease progression [97].  
Nk cells help in maturation of DCs in peripheral tissue (at sites of inflammation) after their 
recruitment from the blood stream. Resulting mature DCs (mDCs) migrate to secondary 
lymphoid tissues, where they prime an antigen-specific T cell response while immature DCs 
are rapidly eliminated from peripheral circulation ensuring that only mature DCs can access to 
inductive sites (to secondary lymphoid tissues). Thus NK cell act as quality control for DC 
populations. This function is impaired in chronic HIV-1 infection [98]. 
Other cellular components of  the innate system include γδ T cells, which are involved in 
early mucosal protection and can lyse HIV-infected target cells [99]. Neutrophils arethe most 
abundant innate immune cells responding early to infections, and possess virocidaleffects on 
HIV [100]. 
1.7.1.4 Interferons 
Interferons (IFNs) are proteins interfering with viral replication by triggering the protective 
defenses of the immune system by activating immune cells, such as natural killer cells and 
macrophages. About ten distinct IFNs (7 for humans) are divided among three IFN classes: 
Type I IFN, Type II IFN, and Type III IFN. Type I interferons include IFN-α (family of 
closely related genes), IFN-β (product of a single gene) and IFN-ω.  
HIV-1 stimulates plasmacytoid dendritic cells (pDC) to produce interferons either TLR7/9 
dependent or independent mechanisms. Downstream molecules involved in TLR dependent 
mechanism include, MyD88, (myeloid differentiation primary response protein 88) interferon 
regulatory factor (IRF)-7 and finally NF-κB activation [101]. On other hand TLR-independent 
induction of type I IFN by viruses is mediated through cytoplasmic sensors, like retinoic acid-
inducible gene I (RIG-I) and the melanoma differentiation-associated gene 5 (MDA5). This 
leads to IRF3 activation and finally NF-κB activation [102].  
Binding of Type I IFNs to their receptors IFNAR (composed IFNAR1 and IFNAR2) 
stimulates the JAK/STAT signal transduction and ultimately leads to transcription of more 
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than hundred ISG (interferon stimulated genes) whose products have antiviral, anti-
proliferative, apoptotic and immunomodulatory properties (Fig 4). The in vitro inhibitory 
effects of IFNα on HIV-1 replication have been described in macrophages, monocytes [103] 
and humanized mouse models of HIV-1 infection [104] some important interferon induced 
proteins are given in table below some of them have already been discussed above in detail. 
 
Fig 1.4: Signaling pathway activated by IFN-α/β. The biological activities of IFN-α/β are 
initiated by binding to the type I IFN leading to activation of the receptor-associated tyrosine 
kinases JAK1 and Tyk2, which phosphorylate STAT1 on tyrosine 701 and STAT2 on 
tyrosine 690. Stable STAT1–STAT2 heterodimer is translocated into the nucleus, where it 
interacts with the DNA-binding protein IRF-9 and a sequence motif (the IFN-stimulated 
response element or ISRE) in target promoters and brings about transcriptional activation. 
Adapted from [105]. 
Interferon-gamma (IFN-γ) is the only member of the type II class of interferons[106] 
produced by natural killer (NK) cells as part of the innate immune response, and by CD4 
(Th1) and CD8 (CTLs) effector T cells once antigen-specific immunity develops [107]. 
Binding of the ligand to IFNGR leads to the activation of the JAK/STAT pathway that 
triggers the gamma-activated factor (GAF) in the nucleus that binds to  
 gamma-activated sequences (GAS) in the promoter region of IFN-γ-induced genes.  
Some effects of Type I and Type II interferons are  
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 Type I and II IFN up-regulate cell-surface MHC class I which is important for host 
response to intracellular pathogens, as it increases the potential for cytotoxic T cell 
recognition of foreign peptides and thus promotes the induction of cell-mediated 
immunity[108]. 
 IFN- γ can efficiently up-regulate the class II antigen presenting pathway and thus 
promote peptide specific activation of CD4+ T cells[109]. 
 Release of cytokines such as interferons and interleukins, that co-ordinate the activity 
of other immune cells. 
 Promote Th1 differentiation by upregulating the transcription factorT-bet, ultimately 
leading to cellular immunity: cytotoxic CD8+ T-cells and macrophage activity - while 
suppressing Th2 differentiation which would cause a humoral response. 
 Up regulates the expression of adhesion molecules such as ICAM-1 and VCAM-1 to 
on target surfaces where leukocyte trafficking is required. 
 Induce the expression of intrinsic defence factors such as TRIM5alpha, APOBEC, and 
tetherin 
Table 1.1: some important Type I and Type II Interferon induced genes/responses. 
Protein induced Effect Reference 
PKR Phosphorylates α-subunit of the protein synthesis initiation 
factor eIF-2α, leading to inhibition of translation. 
[110] 
(OAS)2’-
5′oligoadenylate 
synthetases 
In the presence of dsRNA, synthesizes 2′5′ oligoadenylates, 
which activate endogenous cytoplasmic RNase L and 
ultimately degradation of viral and cellular mRNA 
[111] 
MxA/Mx1, Belongs to superfamily of GTPases. Appears to sense 
nucleocapsid-like structures and trap them into specific 
subcellular compartments to make them unavailable for the 
generation of new virus particles.  
[112] 
Protein IP-10 or 
Chemokine (CXC 
motif) ligand 10  
IP-10 binds to the CXCR3 receptor and acts as a 
chemoattractant for monocytes / macrophages, T cells, 
natural killer cells and promotes their adhesion to 
endothelial cells thus modulating cellular trafficking. 
[113, 114] 
 
Tetherin Viral restriction factor [115] 
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TRIM5α  Viral restriction factor [69, 116] 
APOBEC3G Viral restriction factor [117] 
 
 
1.7.2 Adaptive immune system 
Antigen specific adaptive immune system starts late after the initial innate responses against 
HIV. Adaptive immune system not only recognizes the “non-self” antigen and tailors the 
responses to eliminate the pathogen infected cells but it also develops the immunological 
memory. Professional antigen presenting cells (APC) like dendritic cells, B-cells and 
macrophages (T cells to a lesser extent) process and present the (HIV) antigens on their 
surface which are recognized by T cells in lymph nodes via T cell receptors (TCR) (Janeway, 
1999). 
Exogenous antigens displayed on MHC class II molecules activates CD4+ helper T-cells 
which differentiate into Th1 or Th2 depending on the magnitude and patterns of TCR, co-
stimulatory and cytokine signals received. Th1 cells response produce pro-inflammatory 
cytokines like IFN-γ, IL-2, and lymphotoxin-α (LTα) activating macrophages, natural killer 
cells (NK), antigen-specific cytotoxicT-lymphocytes thus leading to "cell-mediated 
immunity". Th2 cells release of IL-4, IL-5, IL-6, IL-10, and IL-13 that activate B-cells to 
produce neutralizing antibodies leading to"humoral immunity(Janeway, 1999). Intracellular 
antigens (produced by viruses replicating within a host cell) are bound to MHC class I and 
activate CD8+ T cells (CTLs). Once activated, CTLs undergo clonal expansion and travel 
throughout the body to kill infected cells by releasing perforin, granulysin and granzyme. 
Upon resolution of the infection, most of the effector cells are cleared away by phagocytes 
while a few will be retained as memory cells. Regulatory T cells (Treg), limits aberrant 
immune responses to self-antigens (Janeway, 1999). Hence adaptive immune system has two 
major arms i.e. cellular and humoral immune responses. 
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Fig 1.5: Th1/Th2 Model for helper T cells and activation of cellular and humoral responses. 
(Adapted from Rang, H. P. (2003) Pharmacology Edinburgh: Churchill Livingstone ISBN: 0-
443-07145-4. Page 223)  
 
1.7.2.1 Cellular responses: 
The cellular immune system consists of CD8cells, involved in the killing of infected cells, and 
CD4 Th1 cells that activate different cells of the immune system.  (Janeway, 1999).  CD8 T 
cells help to control HIV replication either by MHC class I-restricted antigen-specificmanner 
to directly kill the HIV infected cells through the production of perforin and granzymes [118] 
or by the expression of membrane-bound Fas ligand inducing apoptosis in Fas expressing 
cells[119].Non-cytotoxic effects of CD8+ T cells include IFN-γ production [120][121], CC-
chemokine production[122]and non-cytolytic antiviral response. 
Substantial evidences like high production of chemokines and strong CD8 cytotoxic antiviral 
responses delaying HIV and SIV infections [123, 124][125], detection of viral-specific CD8+ 
T cell inhigh exposed seronegative individual and strong enhancement of the SIV replication 
after in vivo depletion of CD8+ cells in monkeys (by infusion of anti CD8 monoclonal 
antibodies) [126] are few examples highlighting the importance of CD8 T cell responses in 
controlling the viral replication. But it is noted that both cytotoxic as well as noncytotoxic 
anti-HIVCTL responses of CD8+ often decline with disease progression [127, 128]. 
Furthermore some LTNP seem to have rather low levels of HIV-specific CTL [129] while 
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some evidences of increased viral load in rapid progressor despite of strong HIV specific CTL 
responses are suggestive of HIVs ability to escape antiviral responses. (See viral evasion 
mechanisms).  
1.7.2.2 CD8+ T cell mediated non cytotoxic antiviral response (CNAR)  
In addition to their MHC class I-restricted antigen-specific CTL effector function, an 
important activity of CD8+ cells is the non-cytolytic suppression of HIV. First experimental 
evidence that CD8+ T cells from HIV-infected individual have an effective anti-HIV immune 
response without killing the infected cell came in 1986[130]. Substantial reduction in virus 
replication was observed when CD8+ T cells from HIV-infected LTNP were co-cultured with 
MHC mismatched CD4 cells acutely infected with HIV [131, 132]. Several groups confirmed 
the findings [133, 134] and this activity has been referred to in different forms, such as CNAR 
(CD8+ T cell non-cytotoxic anti-HIV response) or CASA (CD8+ anti-HIV suppressor 
activity). 
CNAR was demonstrated with heterologous effectors and targets, suggesting that it was not 
restricted by MHC class I antigens [131]. This noncytolytic suppressive activity was also 
observed when infected CD4 cells were separated by a trans well devices or by adding cell-
free culture fluids from CD8+ T cells of HIV-seropositive persons to infected CD4 cells 
(although maximal effect is observed when cells are in contact ) [135]. Both of these 
observations provided evidence that CNAR is mediated by a soluble secreted antiviral factor 
that has been termed as the CD8+ T cell antiviral factor (CAF). In contrast, the term CNAR is 
used to describe one or more antiviral factors secreted by CD8+ T cells.  
CAF is predicted as 10–50 kD protein, found to be Serine protease sensitive. It is produced at 
low levels and resistance to heat (86C, 10 min) and low pH (2.0) [136].Studies show that 
culture  fluids  from  CD8+ T cells  of  asymptomatic infected persons  can produce more CAF 
and thus better control the virus replication as compared to cells  from  AIDS  patients . This 
suggests that CAF production is dependent on the clinical state of the infected individual. 
Furthermore, an inverse correlation was found between viral load and in vitro CAF 
production i.e. a person with a high CD8+ T cell  antiviral  response  would  have  a  low  
virus  load  and  vice versa suggesting that, the loss of CNAR or CAF production may 
contribute to the inability of AIDS patients to control the viral replication[137]. CNAR/CAF 
is found to be effective before the onset of any humoral response (Ab production) [138] and is 
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also observed in high risk seronegative subjects, elite controllers [139]. Potent CD8 
+inhibitory activity or CAF has  been noted in the simian immunodeficiency virus  (SIV) 
infected macaques [133] SIVsm-infected sooty mangabey  [140] the SIVagm-infected African  
green  monkey model [140, 141] and the HIV-1-infected chimpanzee [142].   
Attempts to reveal the suppression mechanism showed that there was no decrease in the 
number of infected cells in the presence of CAF but a decrease in the expression of viral RNA 
species indicated that CAF was able to suppress the transcription of HIV-RNA [143]. Further 
investigation indicated that CAF can control HIV replication at the level of the HIV long 
terminal repeat (LTR)–driven transcription as a marked decrease in the expression of 
luciferase reporter gene linked to LTR was observed when CD4 infected cells were treated 
with CAF containing fluids. In an attempt to clarify the molecular mechanisms CAF was 
shown to elicit its response by activating the signal transducer and activator of transcription 1 
(STAT1) protein leading to IRF-1 induction and inhibition of gene expression regulated by 
the HIV-1 LTR. [144].  
Several cytokines produced by CD8 cells can inhibit HIV replication in vitro, however studies 
have demonstrated that CAF is not related to any known cytokine or chemokine For example, 
although the β-chemokines can block HIV replication [63], they are distinct from CAF as β-
chemokines block replication of  only  R5 strains while CAF can block the  replication  of  all  
types  of  HIV [145]. Furthermore, neutralizing antibodies to RANTES, MIP-1α, and MIP-1 β 
were unable to substantially block viral suppression [146]. Furthermore, β-chemokines block 
the entry of HIV into the cell, whereas CAF blocks virus production at the level of 
transcription. Baier et al [147] attributed the CNAR activity to IL-16 but the fact that 
relatively high  concentrations of recombinant human  IL-16 were necessary to inhibit virus 
production from primary cells doubted these findings.  
 
Others demonstrated that the chemokine stromal-cell derived factor 1 (SDF-1) and/or 
macrophage derived chemokine (MDC) may be CAF. The role of α- defensins in CD 8-
suppression was proposed and then retracted. Although a large number of interleukins, 
interferons, chemokines, granzymes, growth factors and other cytokines, with anti-HIV 
activity were initially considered as possible CAF candidates but till date none of them fully 
attributes to CAF properties. Some of them are listed in table 2.  
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According to one hypothesis by J.A. Levy, CD8 cells produce a protease (serine protease) and 
a CAF- precursor protein. The precursor is cleaved by the protease to become active as an 
antiviral protein most probably at the cell surface. Whether a proteolytic step is needed to 
activate a CD8 cell product or it affects the infected CD4 cell directly to establish an antiviral 
state requires further study [148]. 
In attempts to define the gene(s) mediating CNAR, differential gene  expression  techniques 
have been used [149] to examine expression pattern of  CD8+ cells from infected subjects 
with high CNAR and CD8+ cells from uninfected controls that lack this activity. Although 
many genes involved in different cellular processes were found to be differentially expressed, 
none of them exclusively identified as CAF and these factors still remained elusive.  
Evidence was presented by Tumne and co-workers [150] linking CNAR to exosomes secreted 
by CD8+ T-cells. They demonstrated that purified exosomes from CD8+ T-cell culture 
supernatant noncytotoxically suppress both (R5) and (X4) of HIV-1 replication in vitro 
through a protein moiety indicating the existence of an antiviral membrane-bound factor 
consistent with the hallmarks defining noncytotoxic CD8+ T-cell suppression of HIV-1. 
However, follow-up studies to identify CNAR have not been published yet.  
In a recent study Scott and coworkers tried to identify the phenotype of CD8 cell subsets 
having strong CNAR activity. They showed that CD8+ T cells from asymptomatic individuals 
with low-level viremia exhibited the highest HIV-suppressing activity and had elevated 
frequencies of CD45RA- CD27+ and PD-1+ (CD279) cells and maximal CNAR activity was 
mediated by CD45RA- CCR7- CD27+ and PD-1+ CD8+ T cells. This study suggested that 
CNAR activity is associated with oligoclonally expanded activated CD8+ cells expressing PD-
1 and having a transitional memory cell phenotype [151]. 
 
 
Table 1.2: Proteins that have antiviral effect but lack identity to the CD8+ T cell antiviral 
factor (CAF). 
 Proteins Reference 
1 Interferon-α , and β [152] 
2 Transforming growth factor-b (TGF-β) [152] 
3 Interleukin-8 (IL-8) [152] 
4 IL-10 [152] 
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5 IL-16 [147] 
6 
ß chemokines: RANTES, macrophage inflammatory 
protein-1a (MIP-1α), MIP-1β 
[63] 
7 Stromal cell-derived factor-1 (SDF-1) [153] 
8 Tumor necrosis factor-a (TNF-α) [152] 
9 Macrophage-derived chemokine (MDC) [154] 
10 Leukemia inhibitory factor (LIF) [155] 
11 Monocyte chemotactic protein-2 (MCP-2) [156] 
12 Lymphotactin [156] 
13 Alpha-defensins 1–3 [157] 
14 RNase [158] 
15 Secretory leukocyte protease inhibitor (SLPI) [159] 
16 Alpha-1-antitrypsin [160] 
17 D Lactoalbumin [161] 
18 6 kD protein [42] [162] 
19 Natural killer cell enhancing factors (NKEF) A, B [53] [163] 
20 CD8 cell product modifying anti-thrombin III [50] [164] 
 
 
1.7.2.3 Humoral responses 
Humoral responses to HIV both against envelope (gp160, gp120, gp41) and core proteins 
(p55, p24, p17) [165] appear generally within 1 to 3 months after infection. HIV-specific IgM 
antibodies that appear at the start of seroconversion start to decline within a few weeks and 
HIV-specific IgG antibodies start to develop [166]. IgG1 is a key player in host defense at all 
stages of infection, and helps to combat the virus with antibody-dependent cellular 
cytotoxicity (ADCC) complement-dependent cytotoxicity (CDC), and complement-dependent 
phagocytosis via Fc mediated effector system [167]. All the other antibody isotypes (IgM, 
IgA, IgG2, IGG4 and IGD) vary in their levels throughout the course of infection. IgA is 
reported to neutralize HIV intracellularly and inhibits its epithelial transfer [168][169] but its 
role in vivo is unclear.  
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Neutralizing antibodies can inhibit virus binding to the target cell or interfere with post-
binding events, including fusion of the virus and cell membranes[170] . High anti-p24 
antibody correlates with slower disease progression. However presence of such correlation 
with gp120 responses has been controversial. Nevertheless the V3 loop [171] as well as 
V1/V2 region of gp120 has been described to elicit neutralizing antibody responses. [172]. 
Furthermore, V1V2 antibodies may confer protection against HIV-1 infection [173]. 
Correlations between humoral responses and disease progression have been established and 
studies show that slow progressors are able to neutralize primary isolates more frequently than 
rapid progressors [174, 175]. Some studies show that HIV specific antibodies have limited 
efficacy during the asymptomatic period, but are unable to clear an infection. 
1.8- Immune evasion of HIV 
HIV differs from many viruses in that it has very high genetic variability. This diversity is 
attributed to fast replication cycle with the generation of about 1010 virions every day, high 
mutation rate of approximately 3 x 10−5 per nucleotide base per cycle of replication [176, 
177], and a high recombination rate [178] that enables the virus to escape from the antibodies 
or cytotoxic T lymphocytes (CTLs). Conserved functional domains of the Env are masked by 
variable loops and only transiently exposed during viral entry [179]. The high degree of 
glycosylation of Env and alterations in the glycan shield of Env during infection also 
contribute to viral escape. This viral camouflage makes the broadly neutralizing antibodies 
very rare. Selection pressure from neutralizing antibody can lead to the change of the antibody 
binding and neutralizing sensitivity [180, 181].  
CTL responses also contribute to immune escape. HIV forms ‘escape mutants’ through 
mutation of viral genes thus altering the antigen processing [182] and loss of epitope binding 
MHC class I making recognition of virus by CD8+ T cells difficult [183-185].  
 
1.9- Non-human primate models for HIV infection  
Non-human primate models for disease pathogenesis are of vital importance for the 
understanding of human diseases. SIV, first isolated in the early 1980's from monkeys with 
AIDS-like disease [186][187] is closely related in genetic structure to HIV-2[188]. It was 
accidently transmitted from juvenile SIV-infected Asian to African macaques when they were 
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kept together in the same enclosure, remarkably at a similar time point when the first cases of 
human AIDS were reported. Experimental inoculation of SIV into a number of Asian 
macaque species, including rhesus, pig-tailed and cynomolgus monkeys, results in 
pathological manifestations similar to AIDS in humans. [189] Currently, the most commonly 
used non-human primate model in HIV research is the SIV infected rhesus macaque mainly 
because rhesus macaques are widely available and numerous laboratory tools for investigating 
immune responses or macaque genetics have been established) [190]. SIV-infection leads to a 
decline in CD4+ T cell populations, immunodeficiency and finally to an AIDS-like illness 
(e.g. Opportunistic infections, neoplastic diseases; hematological and neurological 
disorders)[190]. Progressive changes in lymph node structure during disease course are very 
similar to that seen in humans [191]. Rapid and selective depletion of memory T cells in gut-
associated lymphoid tissues during SIV infection is also confirmed in HIV infection [192]. 
Both viruses, replicate not only in activated and proliferating T cells, but also resting T cells 
and in macrophages [193]. Acute infection in HIV-1 and SIV models resolves with the onset 
of antigen-specific immune responses [194]. Evasion tactics including modification of 
glycosylation patterns in viral envelope protein and mutations in neutralization and CTL 
determinants [195], are also shared by both viruses. In both HIV and SIV infections, plasma 
viral load after the acute phase (“viral setpoint”) is associated with the rapidity of disease 
progression [196]. Survival time is in macaques as variable as in humans but shorter with an 
average of 8-10 years for humans vs. 0.5-3 years for macaques infected with the majority of 
pathogenic SIV strains. However, SIVmac-infected controllers can survive the infection for 
more than 7 years, and one macaque surviving even more than 13 years with ongoing viral 
replication has also been observed (Christiane Stahl-Hennig, personal communication). SIV 
isolates also utilize the CCR5 coreceptor for viral entry [197][198]. However, in contrast to 
HIV-infection no switch in the utilization of coreceptors occurs [199].  In conclusion common 
features between HIV-infected humans and SIV infections in macaques define the unique 
advantage of using this model for the study of HIV pathogenesis.  
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Material and Methods 
2.1 Material  
Table 2.1: General laboratory equipments and consumables. 
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Sterile cell culture work bank  ThermoScientific  
Real-time pcr system 7500  Applied Biosystems  
LSRII (multi-laser flow cytometer)  BD bioscience  
Thermal cycler my cycler  Bio-Rad  
Centrifuge 5415 r, 5417 r, 5424, concentrator plus  Eppendorf  
Pipettes (1-10 µl, 10-100 µl, 2-200 µl, 100-1000 µl)  Eppendorf  
Centrifuge 3 s-r  Heraeus  
Shaker multi bio 3d, mini rocker mr-1  Kisker  
Microbiological safety cabinet  KOJAIR Ltd  
-80°c freezer ultralow u57085  Labotect  
Incubator series 5400  NAPCO  
Microscope ix70 with ccd device and fluorescence imaging unit  Olympus  
Spectrophotometer nanodrop  PEQLAB  
M48 automated system  Qiagen 
-20°c freezer, 4°c fridge  Liebherr 
Centrifuge sorvall discovery 90 with rotor tft 80.4  ThermoScientific  
Inverted microscope, axiovert 25  Carl Zeiss GmbH 
Nitrogen tank Chronos Messer 
Vortexer Ernst Schütt jr 
Microamp optical 96-well reaction plate  Applied Biosystems  
Parafilm   Carl Roth  
Reaction tube (1.5 ml, 2 ml)  Eppendorf  
Pipettor  Hirschmann  
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Centrifugation tube (15 ml, 50 ml)  Greiner Bio-One  
Agar dishes (100 mm)  Sarstedt  
Pipette tips rnase/dnase free (10 µl, 100 µl, 200 µl, 1000 µl),  Sarstedt  
Reaction tube (0.2 ml, 0.5 ml, 1.5 ml)  Sarstedt  
Dishes (60 mm, 353004; 100 mm, 353003)  bd falcon BD Falcon 
Multi   well   plates   (12-well,   353043;   24-well,  353047) BD Falcon 
Freezing device “mr. Frosty” Nalgene 
Neubauer counting chamber Carl Roth 
Water bath GFL 
Cell scraper Kisker 
Cryotubes (1.8 ml) NUNC (ThermoScientific) 
Flasks (250 mm 2 , 750 mm 2 , 1750 mm 2 ) Sarstedt 
Serological pipette (2 ml, 5 ml, 10 ml, 25 ml) Sarstedt 
Cover slips ThermoScientific 
Leukosep tubes Greiner 
Macs multistand Miltenyi Biotec 
Macs separation columns ms and ls Miltenyi Biotec 
Tissue culture treated paltes  BD falcon 
Non tissue culture treated plates BD falcon 
Multichannel micropipette  
 
 
Table 2.2: Chemicals and Reagents. 
Reagent/ chemical Source 
Trypsin, trypsin/EDTA 0.25% PAA laboratories 
Penicillin/streptomycin PAN Biotech 
Fetal  calf  serum,   PAA laboratories 
RPMI 1640 cell culture medium PAA laboratories 
Dimethylsulfoxid (DMSO)  Sigma Aldrich 
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Nuclease free water  Merk 
Ethidium bromide  Applichem 
Ethanol  Roth 
Formaldehyde (37%) Roth 
Concanavalin-A SERVA 
DPBS  Gibco  
Milk powder Roth 
Β-mercaptoethanol  Roth 
Fetal calf serum PAN Biotech 
Interleukin 2 (IL-2) Pepro Tech 
Rhesus Interferon -α PBL biomedical laboratories 
Rhesus Interferon -γ PBL biomedical laboratories 
Rhesus TNF- α PBL biomedical laboratories 
Isopropanol Roth 
Methanol Roth 
QIAshredder columns  Qiagen 
dNTPs (10 mM each) Fermentas 
Loading dye (6x)   Bioline 
Agrose Biozyme 
FACS flow, FACS rinse , FACS safe BD biosciences 
Lymphocyte separation medium PAA laboratories 
MACS Bovine-Serum-Albumin (BSA) Miltenyi Biotech 
DMEM   PAA laboratories 
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Table 2.3: Reaction components and commercial kits 
Kit/component  Source 
Quantitect probe RT-PCR kit  Qiagen 
BigDye Cycle Sequencing Kit Applied biosystem 
Immomix Bioline 
CloneJET1.2 PCR Cloning Kit Fermentas 
Superscript III First strand cDNA synthesis kit Invitrogen 
PAXgene blood RNA kit and tubes PreAnalytix 
Endo Free plasmid mini kit   Qiagen 
 RNA easy plus mini kit Qiagen 
Endo Free plasmid maxi kit   Qiagen 
Phusion PCR Master Mix Thermo scientific 
Gel extraction Kit Qiagen 
Bgl 11 enzyme and orange buffer Fermentas 
TransIT transfection reagent kit  MIRUS 
Retronectin Takara/clontech 
10x ROX Bioline 
Anti-mouse anti CD3 antibody  Becton Dickinson 
Sybr green Bioline 
  
 
Table 2.4: List of Antibodies 
Name Clone Isotype Fluorochrome 
CD4 MT477 Ms IgG1 k PE 
CD8 SK1 Ms IgG1 k PE 
CD11a HI111 Ms IgG1 k PE 
CD27 MT271 Ms IgG1 k PE 
CD28 28.2 Ms IgG1 k PE 
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CD45 TU116 Ms IgG1 k PE 
CD45RA 2H4 Ms IgG1 k PE 
CD62L SK11 Ms IgG2a k PE 
CD64 10.1 Ms IgG1 k PE 
CD80 L307.4 Ms IgG1 k PE 
CD86 B70/B72 Ms IgG1 k PE 
CD95 DX2 Ms IgG1 k PE 
CD122 Mikb2 Ms IgG1 k PE 
CD127 hIL-7R-M21 Ms IgG1 k PE 
CD153 RM153 Rat IgG2b PE 
CD154 TRAP1 Ms IgG1 k PE 
CD183 1C6/CXCR3 Ms IgG1 k PE 
CD184 12G5 Ms IgG2a k PE 
CD193 61828.111 Rat IgG2a PE 
CD195 3A9 Ms IgG2a k PE 
CD196 11A9 Ms IgG1 k PE 
CD197 3D12 Rat IgG1a k A647 
TCRab R73 Ms IgG1 k PE 
HLA-DR L243 Ms IgG2a k PE 
CD271 C40-1457 Ms IgG1, κ PE 
CD3 SP34 Ms IgG3, λ PE 
CD271  C40-1457 Ms IgG2a k APC 
CD4 L200 MsIgG1k Per-CP-cy55A 
CD8 Sk1 MsIgG1k Amcyan-A 
CD69 TP1.55.3 MsIgG2bk ECD 
HLA-DR L243 MsIgG2ak APC-Cy7 
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2.2 Methods 
2. 2.1 Experimental animals 
To identify the CNAR/CAF+ animals (whose CD8+ T cells were having the ability to suppress 
the viral replication), in vitro viral inhibition test was performed with CD8+ T cells from 11 
SIV-infected and 9 non-infected rhesus macaques (Macaca mulatta) of Indian origin. CD4+ T 
were isolated from MHC-mismatched non-infected rhesus macaques of Indian origin.  
At latter stage of study, samples from two vaccine experiments were also included to monitor 
the changes in expression pattern of selected genes upon immunization and infection. First 
experiment (Exp-1) included24 animals, while Second group (Exp-2) included6 control (non-
vaccinated) and 12 vaccinated animals. 
All animals are housed at the German Primate Centre under standard conditions according to 
the German animal protection law which complies with the European Union guidelines on the 
use of non-human primates for biomedical research. Animals were handled by the 
veterinarians and animal keepers of the Department of Infection Models. All samples were 
processed at biosafety level II. 
 
2.2.2 Preparation of virus stock  
To prepare virus stocks, 15 million CEMx174 cells were pelleted and re-suspended in 1ml 
SIVmac239 virus stock. Suspension was incubated for 1.5hours at room temperature with 
intermittent swirling every 15 min. Cells were re-suspended in RPMI 1640 complete medium 
containing 10% (vol/vol) heat-inactivated (56°C, 30 min) foetal bovine serum (FBS) (PAA 
Laboratories), 1% streptomycin (PAN biotech). After 24 hours incubation at 37°C (CO2 5%), 
residual virus was washed out twice and cells were incubated for next three days. On day 3 
cultures were replenished with new complete RPMI and returned to incubator till day 6. Cell 
culture supernatants at day 6 and day 7 were collected. After filter sterilizing with 0, 45µm 
filter, samples were frozen at -80°C.  
 
2.2.2.2Virus titration 
Virus stock was titrated to determine the exact TCID50.  For this purpose, 3 × 104 C8166 cells 
in 50 µl of RPMI complete medium were plated in each well of a 96 well plate. 100 µl of 10 
fold serially diluted virus stock was added in 8 replicates. Negative controls contained 
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medium only. After 4 days of incubation, cell culture medium was replaced by fresh RPMI 
complete medium. At day 7, virus titer was determined by indirect immunoperoxidase assay.  
 
2.2.2.3 Indirect immunoperoxidase assay 
A 96 well plate was equilibrated with 200 µl of RPMI complete media overnight (4°C) or 1 
hour (room temperature RT). The plates were coated with 50 µl/well of Concanavalin-A 
(ConA) at a concentration of 0.5mg/ml in phosphate buffer saline (PBS) and incubated for 1 
hour at RT. Plates were either used immediately or frozen at -20°C till needed. Using a multi-
channel micropipette, cells from the virus titration assay (2.3) were re-suspended and 
transferred to respective ConA coated plates. After incubating at 37°Cfor 2 hours, plates were 
than decanted and cells were immersed in pre-chilled (-20) methanol for 30min or overnight at -
20. Plates were carefully washed thrice with cold PBS and blocked with 100 µl/well of 2% 
milk powder (MP) at RT for 30-60 min. MP was discarded and plates were incubated at 37°C 
for another 30-60 min with 50µl/well of a 1:3000 diluted (in MP) polyclonal SIV anti-serum 
from a chronically infected macaque (SIV.S 1604, DPZ). Another washing with PBS was 
followed by similar incubation with 50 µl/well of 1:1000 diluted anti-human Ig-HRPO 
conjugate. Plates were washed with PBS and incubated with 50 µl substrate solution (2mg 
AEC, 300 µl DMF, 25 µl of 30% H2O2 and 5ml sodium acetate) for 20-30 min. The reaction 
was stopped by twice washing in PBS and plates were examined immediately for stained cells 
under an inverted light microscope. The TCDI50 was scored using the Reed and Muench 
method as described elsewhere (Fridholm&Everitt, 2005; LaBarre& Lowy, 2001) 
 
2.2.3 Preparation of peripheral blood mononuclear cells (PBMCs) 
Peripheral blood mononuclear cells (PBMCs) were isolated from the blood by Ficoll density 
gradient centrifugation. Ficoll (Lymphocyte separation medium, PAA Laboratories) laid 
blood was centrifuged at 1045xg for 25 min in 50 ml Leukosep- 
Tubes (Greiner).  The buffy layer containing lymphocytes was collected and washed twice 
with 10ml PBS by centrifugation for 10min at 300xg. Cell were counted during second wash 
step using trypan blue exclusion method allowing counting of only live cells on 
haemocytometer (Neuberger, Germany) 
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2.2.4 Enrichment of specific cell types 
Specific cell types (CD4+ T cells, CD8+ T cells, B cells, NGFR+ T cells) were isolated by 
magnetically labelled antibodies cell separation technique (MACS) (Miltenyi Biotech). 
Lymphocytes were suspended in MACS buffer (1:20 dilution MACS BSA Stock Solution 
with auto MACS Rinsing Solution Miltenyi Biotec) and incubated with respective antibodies. 
(CD8-PE 10 µl, NGFR-PE 40 µl, CD4-beads 20 µl, CD20-beads 20 µl) for 10-20 min as specified 
in the respective protocol. The CD4 and CD20 (for B-cells) antibodies were directly 
conjugated to magnetic beads (CD4 and B cells) whereas the CD8 and anti-NGFR were 
coupled to Phycoerythrin. Cells labelled with PE-coupled antibodies needed additional 15 min 
incubation step with 20 µl of anti-PE magnetic beads. Applying the labelled cell suspension 
on MS columns (Miltenyi Biotec) allowed the unbound cells to pass through and retained the 
positive cells on column that were eluted in the subsequent wash step with MACS buffer. 
 
2.2.5 Invitro viral inhibition assay 
Viral inhibition assays were performed to estimate the inhibitory capacity of CD8+ T cells on 
in vitro replication of SIV. In principal, CD4+ T cells from SIV-uninfected, MHC-mismatched 
donor animals and CD8+ T cells from experimental animals were isolated by MACS as 
described (section 2.4).Purity of isolated cells was checked with FACS (section 2.12).  These 
cells were then activated with Concanavalin-A (ConA) (10ng/ml) for 24 hours at 2 × 106 
cells/ml of RPMI complete medium. Cells were washed and CD4+ T were infected with 
SIVmac239 at a multiplicity of infection (MOI) 0,001 TCID50for 2 hours with intermittent 
swirling every 15 min. After washing twice with RPMI complete medium, cells were re-
suspended at a concentration of 2 × 106 cells/ml in the RPMI 1640 complete medium 
supplemented with 100 U/ml recombinant human IL-2 (Pepro Tech). In vitro infected CD4+ T 
cells were either cultured alone (controls) or co-cultured with ConA activated CD8+ cells from 
experimental animals in duplicate at a 2:1 (CD8+T cell: CD4+T cell) cell input ratio.5 × 105 
CD4+ T cells and 1 × 106 CD8+ T cells were co-cultured in each well of a 24 well plate. Cells 
were incubated in sterile conditions at 37°C in a 5% CO2 humidified chamber. Old culture 
medium was replaced with fresh RPMI complete medium at day 3. Supernatants were 
collected at day 5 and 7 for viral RNA isolation. CD8+ T cells were re-isolated from the co-
cultures at D7 and were subjected to Microarrays analysis to find the genes differentially 
expressed in the CD8+T cell of CNAR+ and CNAR-  animals. 
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Fig 2.1: A schematic representation of in vitro viral inhibition /CAF test. 
 
2.2.6 Viral RNA extraction and quantification 
Viral RNA from 200 µl of culture supernatant at day 5 and day 7 post infection were isolated 
by using the BioRobot® M48 workstation and theMagAttract Virus Mini M48 protocol 
(Qiagen, Hilden, Germany). This automated RNA isolation procedure involves initial lysis in 
protease and Al buffer. After lysis, viral RNA is bound to MagAttract suspension beads. 
Successive steps include automated washing with buffer AW1, AW2 and ethanol followed by 
elution of viral RNA in 75 µl of buffer AVE. Viral RNA was quantified using TaqMan probe-
based one-step RT qPCR on an ABI-Prism 7500 sequence detection system (Applied 
Biosystems) and in the presence of standard RNA.  
Quantitect probe RT-PCR Kit (Qiagen) was used for this purpose. Use of 2x QuantiTect 
Probe RT-PCR Master Mix (HotStarTaq DNA Polymerase,  QuantiTect  Probe  RT-PCR  
Buffer, and ROX passive reference dye) and QuantiTect RT Mix (Omniscript and Sensiscript 
RT blend), together with SIV primers SIV gag forward: 5’-
ACCCAGTACAACAAATAGGTGGTAACT-3’. SIV gag reverse: 5’-
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TCAATTTTACCCAGGCATTTAATGT-3’ and probe (FAM 5’-
TGTCCACCTGCCATTAAGCCCGAG-3’-TAMRA) (M33262) allowed both reverse 
transcription of RNA (100ng) and PCR to take place in a single tube. Quantity of each 
component is given in Table 2.5. 
Amplification conditions were as follows: reverse transcription: 50°C (30 min); activation:  
95°C (15 min); amplification: 45 cycles of denaturation at 94°C (15s); extension/annealing 
60°C (60s). Amplified viral RNA was expressed as SIV-RNA copies /ml supernatant.  
 
 
 
  
 
 
 
 
 
 
 
 
 
Table 2.5: Reaction components and their respective concentration for cDNA synthesis. 
 
2.2.7 Cellular RNA extraction 
Total CD8+ T cellular RNA was isolated with RNeasyPlus Mini Kit according to the 
manufacture´s instruction (Qiagen). Briefly, proteins were denatured by suspending the cells 
in RLT buffer (guanidine isothiocyanate with 1% β-mercaptoethanol) and centrifugation 
(Table-top centrifuge 5417 R, Eppendorf) in a QIAshredder column (Qiagen). Genomic DNA 
(gDNA) was removed by passing the homogenized lysate through gDNA eliminator spin 
column, allowing only unbound cellular RNA to pass through. After precipitation with 70% 
ethanol, RNA was bound to membrane of RNeasy spin columns and subsequently washed 
with RW1 and RPE Buffers. Finally RNA was eluted with 20 µl of RNase-free water. 
Quantity of isolated cellular RNA was determined by spectrophotometer (Nano Drop,PeqLab) 
using RNAse free water as reference. Quality of RNA was checked by Agilent 2100 
Component Volume Final Concentration  
TaqMan Probe 0,375  µl 0,2 µM 
SIV gag forward primer  0,625  µl 
 
0,4 µM 
SIV gag reverse primer 0,625  µl 
 
0,4 µM 
RNasefree water 5,625 µl 
 
- 
2x QuantiTect RT-PCR master mix 12,5  µl 
 
1x 
QuantiTect   RT-mix  
 
0,25  µl - 
RNA  5  µl 
 
 
Total 25 µl 
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Bioanalyzer (Agilent Technologies). Average RIN values (RNA Integrity Number) for most 
samples was greater than 8.5. RNA was either stored at -80°C or immediately used for cDNA 
synthesis. 
 
2.2.8 RNA isolation from blood 
From whole blood collected in a PAXgene Blood RNA Tube (PreAnalytix), total cellular 
RNA was manually isolated by PAX gene Blood RNA Kit according to the instruction of the 
manufacturer (Qiagen). PAXgene Blood RNA Tubes contain a special RNA stabilization 
reagent that protects RNA molecules from degradation by RNases thus minimizing the ex vivo 
gene expression changes. Previously frozen blood was first incubated at room temperature for 
2 hours in order to achieve complete lysis. To begin with purification, blood was centrifuged 
at 3000×g for 10 min to pellet nucleic acids. After washing with RNase free water, the pellet 
was incubated in optimized buffers together with proteinase K (55°C, 10 min) for protein 
digestion. Centrifugation at maximum speed (3 min) through the PAXgene Shredder spin 
column allowed homogenization of the cell lysate and removal of residual cell debris. 100% 
ethanol was added to supernatant of the flow-through and applied to a PAXgene RNA spin 
column. During 1 min centrifugation at 17000 rcf, RNA was selectively bound to the 
PAXgene silica membrane and contaminants pass through. Remaining contaminants were 
removed in several wash steps. Between the first and second wash steps, the membrane is 
treated with DNase I (at room temperature for 15 min) to remove trace amounts of bound 
genomic DNA. After the final wash steps, RNA was eluted in 40 µl elution buffer and heat-
denatured (65°C, 5 min). 
 
2.2.9 Primer design and optimization 
The cDNA sequences used for the primer design were taken from Genbank of National 
Centre of Bio-Informatics (NCBI) and EMBL (European Molecular Biology Laboratory). 
Primers for target genes were designed by NCBI primer3online software 
(http://www.ncbi.nlm.nih.gov). Special attention and precautions were taken to avoid 
secondary structures or dimers. The lengths of the amplicons were kept between 80bp to 
150bp.Specificity was determined by agarose gel electrophoresis of PCR fragments and by 
checking the dissociation curve. Efficiency was tested by amplifying serial dilutions of cDNA 
with various primer concentrations. 
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Only reaction conditions with efficiency of amplifying the target sequence more than 95% 
were used for further experiments. App Table 1 summarize the primer sequences used for 
amplification of selected genes along with amplicon lengths. The sequences for the GAPDH 
and MxA primers were already described by [200] and [201]respectively. 
 
2.2.10 cDNA synthesis 
For initial experiments (candidate gene expression in CD8+ T cells) 500ng RNA was reverse 
transcribed using SuperScript III First-Strand Synthesis System (Invitrogen) according to the 
manufacturer´s protocol. For initial denaturation each 10 µl reaction mixture containing  500 
ng RNA, 50 ngOligodT primers and 10 mMdNTP was incubated at 65°C for 1 min. 10 µl  
master mix containing, 10 x RT buffer, 25 mM MgCl2, 0.1 M DTT, 40 U RNase Out and  200 
U of SuperScript III was added to each reaction mix. No-reverse transcriptase reaction (NRT) 
that lacked the reverse transcriptase was included to assure there is no gDNA contamination. 
The reaction condition for cDNA synthesis were as follows 
Hybridization: 10 min 25°C  
Elongation     : 50 min 50°C  
Stopping        : 5 min 85°C  
cDNA was directly stored at -20°C and was used later on for RT-PCR. 
RNA isolated from whole blood was reverse transcribed by QuantiTect Reverse Transcription 
Kit (Qiagen). Reaction comprises two main steps: elimination of genomic DNA and reverse 
transcription. In the first step gDNA was removed by incubating 100ng RNA with gDNA 
wipeout buffer for 2 min at 42°C. In the second step a master mix prepared from Quantiscript 
Reverse Transcriptase (1 µl), Quantiscript 5x RT Buffer5x (4 µl) and RT Primer Mix (1 µl) 
was added to the reaction mixture. Reaction was started at 42°C for 15 min and then was then 
terminated at 95°C for 5 min. cDNA samples were stored at -20°C for subsequent use in RT-
PCR. 
 
2.2.11 Real Time PCR quantification of cellular genes 
Expression of cellular genes was quantified by Real Time PCR in an ABI Prism 7500 cycler. 
Reactions were performed in 96 well MicroAmp Optical Reaction Plates (ABI). Each 25 µl 
reaction mixture contained 12.5 µl Immomix (Bioline), 6.6 µl 10xRox (Bioline), 0.5 µl Sybr 
green (Bioline), 2 µM of each primer, and 2 µl of 1:5 diluted cDNA products. The reactions 
were run as one cycle at 95°C (7 min) followed by 40 cycles at 95°C (15 s) and 60°C (33 s). 
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Additional melting temperature detection step was included to ensure the amplification of 
right product. No-reverse transcriptase (NRT) and Non-template controls (NTC) were run 
simultaneously. RNA levels of the housekeeping gene Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were determined as reference for calculating the relative expression 
levels of the target genes. All samples were run at least in duplicates. The results were 
analysed by Sequence Detection Software (ABI). The relative expression level was calculated 
as the difference between the mean Ct values (calculated from the duplicates) of each 
target and reference gene GAPDH (Mean ∆ Ct = Ct (target gene) - mean Ct (GAPDH). 
 
2.2.12 Flow cytometry 
For qualitative as well as quantitative analysis of desired cell surface molecules, 
flowcytometry analysis was performed using LSR II Flow cytometer (BD).  Approximately 5 
× 105 cells were washed with FACS-PBS (PBS supplemented with 0.1% BSA, 0.03% 
sodiumazide, pH 7.2) and fluorescently labelled antibodies for 30 min at 4°C.  Cells were than 
washed with FACS-PBS and fixed in 1.5 ml of formaldehyde (7% in PBS) in dark at room 
temperature. After washing, the cell pellet was suspended in 50 µl of PBS and  
stored at 4°C in the dark. Samples were measured by BD FACSDiva software (BD 
Biosciences) and later data was analysed with FlowJo version 6.4.7 differentiating positive, 
double positive and negative cells. Antibodies used are given in table 2.4. 
 
2.2.13. Cloning and sequence analysis of FAM26F 
2.2.13.1 PCR-amplification of FAM26F 
FAM26F gene from previously characterized CAF+ and CAF- group of animals was cloned 
and sequenced. For this purpose FAM26FcDNA was amplified using Phusion High-Fidelity 
PCR Master Mix (Thermo Scientific). The components and their respective concentrations 
used per reaction are given in table 2.6 Primers (forward 
5’-GGACGAGGCTCATGGAGAAG-3’; reverse, 5’-AAGGTCATAACCCAGGAGTGC-3) 
used in this reaction were designed as described (section2.9). The primers amplify the cDNA 
sequence of FAM26F from position 155 to 1117 (963bp product) encompassing the whole 
protein coding region.  PCR conditions were as follows: initial denaturation at 98°C for 3min, 
30 cycles of denaturation 98°C (30s); extension/annealing 58°C (30s) with incrementsof4sat 
each cycle and 72°C (10min). 5 µl of PCR product was run on 1% agarose gel to confirm the 
expected 971bp FAM26F product. 
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Components  Volume 
Water    32,5 µl 
5x Phusion HF Puffer  10 µl 
Forward Primer 10 µM 2,5 µl 
Reverse Primer 10 µM  2,5 µl 
dNTP 10 mM   1 µl 
Phusion DNA Polymerase  (2 U/ µl) 
  
0,5 µl 
cDNA   1 µl 
 
Table 2.6: Reaction components and their concentrations for PCR. 
 
2.13.2 Extraction and purification of DNA from agarose gel 
DNA band from the agarose gel was excised with a clean, sharp scalpel and weighed. DNA 
was extracted using QIAEXII Extraction kit (Qiagen) according to the instructions of the 
supplier. Addition of Buffer QX1 in 1:3 (by weight) solubilised the gel by disrupting the 
hydrogen bonds between sugars. Mixture was incubated with QIAEX II at 50°C for 10 min 
and vortexed after every 2 min. This allowed the DNA to quantitatively adsorb on the QIAEX 
II silica-gel particles. After centrifugation for 30s, supernatant was removed and the pellet 
was washed twice with 500 µl of Buffer QX1. Pellet was air dried. DNA was eluted by 
adding 20 µl of 10 mMTris-Cl (pH 8.5) to the pellet and centrifuging at 17000 rcf for 30 s. 
The supernatant containing purified DNA was carefully pipetted into a clean tube. Product 
was later confirmed by running 1 µl of the extracted sample on 1% agarose gel and quantified 
using NanoDrop (PeqLab) spectrophotometer. 
   
2.13.3 Cloning 
CloneJET™ PCR Cloning Kit (Fermentas, now Thermo Scientific) was used for cloning of 
bluntend DNA fragments. Briefly stating, 10 µl of 2X Reaction Buffer, 0.05 pmol of 
pJET1.2/blunt Cloning Vector, 1 µl of T4 DNA Ligase and 0.15 pmol of purified DNA 
fragment were mixed and scaled up to 20 µl by adding nuclease free water. Mixture was 
incubated for 30min at room temperature.  
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This ligation mixture was then used to transform TOP10 E.coli strain by using heat schok  
transformation method. Ligation mixture was added to the competent cells.Cells were given a 
heat shock by placing first at 42°C for 1min and then immediately transferring them to ice. 
After adding 1ml LB media, transformed cells were agitated at 200 rpm for 1hour at 37°C and 
then centrifuged for 1min at 300xg. 900 µl of the supernatant was discarded and 150 µl of 
cells were streaked on pre-warmed ampicillin selective agar plates. Plates were incubated 
overnight at 37°C and subsequently stored at 4°C. 
 
2.13.4 Purification of plasmid 
For sequence analysis FAM26F small scale plasmid production was done. Positive clones 
from agar plates were picked and a starter culture of 2–5 ml LB medium containing ampicillin 
(100µg/ml) was inoculated. These bacterial cultures were incubated for approximately 8 hours 
at 37°C with vigorous shaking. For cell culture applications, large scale endotoxin free 
plasmid preparation was required. For this purpose, a starter culture of 5ml LB-ampicillin 
medium was set up (as for small scale production) and this culture was used further to 
inoculate 100ml of LB-ampicillin medium. Cultures were incubated for approximately 14-16 
hours at 37°C with vigorous shaking. Cells were harvested by centrifugation at 6000 x g for 
15 min at 4°C. 
Plasmids were purified from bacterial cells using plasmid isolation Mini (for small scale 
production) or Maxi (large scale production) kits (Qiagen). Briefly, bacterial cell pellet was 
first re-suspended in Buffer P1 and then incubated with P2 at room temperature for 5 min to 
precipitate genomic DNA and cell debris. Chilled buffer P3 was added and after vigorously 
inverting the tubes 4–6 time, mixture was incubated on ice for 5 min. After centrifugation at 
maximum speed in which centrifuge or g numbers for 10 min supernatant containing plasmid 
DNA was promptly applied to pre-equilibrated (buffer QBT) QIAGEN-tip 20. After washing 
the column twice with buffer QC, plasmid DNA was eluted with buffer QF. Isopropanol 
precipitation and centrifugation was followed by washing with 70% ethanol. Resulting pellet 
was air dried, dissolved in a TE buffer (pH 8.0) and concentration was determined by 
NanoDrop (PeqLab) spectrophotometer. 
 
2.13.5 BglII restriction digestion 
BglII restriction digestion was performed to identify the positive colonies carrying 
FAM26FcDNA fragment. For this purpose 1µg of plasmid (propagated and isolated from 
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selected colonies) was incubated overnight at 37°C along with 1U of Bgl II enzyme 
(Fermentas) and orange buffer (Fermentas). Product was run on 1% agarose gel and positive 
clones were further subjected to sequencing. 
 
 
2.13.6 DNA sequence analysis 
Sequencing was performed using Big Dye Terminator sequencing kit (ABI). Beside vector 
specific Forward 5’- CGACTCACTATAGGGAGAGCGGC -3’ or reverse primer 5’- 
AAGAACATCGATTTTCCATGGCAG -3’ (provided with CloneJET™ PCR Cloning Kit), 
two internal primers were also used for complete sequencing. Internal Forward 5’-
CTATTTGGAACAGGAGCAGC-3’ Internal reverse 5’-CAGTTG TGGTCGCGGTCGAG-
3’. 20  µl sequencing reaction contained 3.3 pmol Primer, 200 – 300 ng plasmid, 1.5  µl 5x 
sequencing buffer and 1  µl Big Dye. Sequencing PCR amplification conditions were as 
follows 25 cycles of 96°C (30 sec), 50°C (15 sec), 60°C (4 min). Ethanol precipitation of PCR 
product was done by adding 250 µl 100 % ethanol and 10 µl 3M sodiam acetate and 
centrifugation at 13.000 rpm (15 min). Product was afterward washed with 250 µl of 70% 
ethanol, air dried in a SpeedVac andsequenced by ABI   PRISM   3130xL   Genetic   Analyzer   
(Applied Biosystems).   
 
2.14 In Vitro stimulation of PBMC with interferons 
In vitro stimulation experiments were performed to study the differential expression pattern of 
desired genes upon activation by Interferon alpha (INF-α), interferon gamma (INF-γ) and 
Tumour necrosis factor alpha (TNF-α). For this purpose PBMCs were isolated from blood 
(section 2.3) and activated by concanavalin-A (10 ng/ml) for 8 hours. After washing twice, 
cells were re-suspended in complete RPMI media supplemented with 100 U/ml recombinant 
human IL-2 (Pepro Tech). Cells were plated in duplicate at a density of 5 × 106 cells/2 
ml/well and INF- α(10 ng/ml), or INF-γ(100ng/ml)or TNF-α(10, 50 or 100ng/ml) were  added 
in respective experiments. In parallel, unstimulated PBMCs were used as controls. Cells were 
harvested by centrifugation at different time points and frozen in RNA later (Qiagen).  
 
2.15 T Cell line development 
The ability of human telomerase reverse transcriptase (hTERT) to stabilize telomere length 
and extend cellular proliferative capacity is well documented. Infecting cultures of antigen 
	

stimulated PBMCs with MuLV-based vectors, carrying hTERT gene results in selective 
immortalisation of primary T cells. To produce the viral vectors, GP2-293 cells were 
transfected with constructs carrying viral envelope (RD114) and human telomerase gene 
(hTERT) genes. Inclusion of a surface marker gene ∆LNGFR (C-terminally truncated human 
low-affinity nerve growth factor receptor) allowed the efficient identification and purification 
of hTERT transduced cells. Fig 2.2 represents different steps of immortalisation procedure. 
 
Fig 2.2: Schematic representation of the steps leading to conversion of primary cells into cell 
line  
 
2.15.1 Culturing of Packaging Cell Line GP2XTERT11 
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The cell line GP2xTERT11 (kindly provided by Eugene Barsov) were maintained in DMEM 
complete growth medium (DMEM supplemented with 10% of FBS, penicillin, and 
streptomycin) and incubated at 37 °C (5% CO2). Cells were split every 3–4 days as per 
routine cell culture practices. For maximal transfection, cells that have been either longer than 
1 month or less than 1 week in culture were avoided. Reselection of packaging function was 
done at intervals by growing the cells for 5 days in the growth medium supplemented with 
aminopterin (0.1 µM), then in HAT medium (DMEM + 10% FBS + HAT Supplement) for 
next 5 days and for last 5 days in the HT medium (DMEM + 10% FBS + HT Supplement). 
After that, the cells were maintained in the regular growth medium. 
 
2.15.2 Viral Vector production 
To produce the viral vector, one day before transfection (D0) 6 million GP2xTERT11 cells 
were plated on 10cm tissue-culture treated polystyrene plates (BD Falcon). On the day of 
transfection (D1), cells were transfected with a plasmid construct carrying Feline endogenous 
retrovirus RD114 envelope gene (kindly provided by Eugene Barsov [202]. 25 µl of TransIt-
293 transfection reagent (Mirus Bio Corporation) was first incubated with 300 µl RPMI 1640 
(FCS and antibiotic free) medium and incubated for 20–30 min at room temperature. Mixture 
was then incubated with 10 µg of RD114 envelope carrying plasmid for 20 min and added to 
the cells. Plated were rocked gently and overnight incubated at 37°C (5% CO2).  24hours post 
transfection (D2), old growth medium was replaced with new DMEM complete medium and 
cells were incubated for another 24 hours. 48hours post transfection (D3) the cell culture 
supernatant was harvested and the equal volume of fresh DMEM complete medium was 
added for a second harvest. Supernatants containing the retroviral vectors were centrifuged at 
3,000–4,000 × g (4°C) to remove residual cells debris and aliquoted to store at -80. 
 
2.15.3 Activation of T Cells 
CD4+ or CD8+ cells were isolated from 30 ml blood as described in section 2.3. 50µgof anti-
mouse anti CD3 antibody (Becton Dickinson) was dissolved in 1ml PBS. Each well of a 12-
well tissue culture plate was coated with 500 µl of this solution. Plates were incubated at 37°C 
for 3 hours and afterwards washed once with PBS. T Cells were re-suspended in complete 
RPMI medium (100U IL-2) at density of 2 × 105cells/ml and plated on antibody coated plates. 
Cells were cultured at 37°Cin a 5% CO2 humidified chamber for 48 hours.  
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2.15.4 Transduction 
12-well non-tissue culture treated plates were coated with 25µg of Retronectin 
(TaKaRa/Clontech) solution in PBS. After blocking the non-specific binding by 2% bovine 
serum albumin (BSA in PBS) for 30 min, wells were washed twice with PBS. Retroviral 
vector stocks (2-5ml/well) were then added to the wells and plates were centrifuged (1950×g) 
at 32°C for 2 hours. 3-4 million activated T cells in the complete RPMI medium 
(supplemented with 100U IL-2) were added to the wells. In one well, 2 × 106 C8166 cells (in 
complete RPMI medium) were added as a positive control of transduction. After 
centrifugation of cells at (215 × g) at 32°C for 30 min, plates were incubated at 37°C (5% 
CO2). Fresh RPMI complete media was added after 24 hours and plates were incubated for 
another 24 hours.48 hours post-transduction, cells were stained with APC labelled anti-NGFR 
antibody (Miltenyi) and analysed by FACS (section 2.12) for the presence of NGFR+ cells. 
Non-transduced cells were used as negative controls for FACS analysis. On the basis of % 
positive cells, the viral titers were calculated as follows:  
Number of viral vector particles = Number of cells initially plated × % of NGFR+ cells. 
2.15.5 Preparation of feeder cells 
For preparation of feeder cells, PBMCs were isolated from buffy coats kindly provided by 
Transfusion Centre University Clinic Göttingen, UMG. PBMCs were isolated by ficoll 
density gradient centrifugation as described in section 2.3. Cells were then resuspended in 
15ml of the complete RPMI media and irradiated with 60 G using γ-irradiator situated at the 
Department of Radiotherapy and Radiation Oncology UMG. After irradiation, cells were 
washed twice with complete RPMI medium and cryo preserved in freezing media containing 
20% FCS and 10% DMSO till further use.  
 
2.15.6 Post transduction cell culturing and sorting 
Once the transduction of xlox (NGFR) TERT in T cells was verified by FACS analysis, the 
transduced NGFR+ cells were purified by magnetically labelled antibodies cell separation 
technique (MACS) (section 2.4)  using anti-NGFR (CD271) antibody (Becton Dickinson). 40 
µl of antibody was used to label 1 × 107 cells and LS columns (Miltenyi) were used for sorting 
of positive cells.  0.5-1 million NGFR+ sorted cells were cultured in T25 tissue culture flasks 
with 4-5 million feeder cells in RPMI medium (20% FCS) supplemented with 30–50 ng/ml 
anti-CD3 antibody. Flasks were initially placed in incubator in upright position for 48 hours. 
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Cells were replenished with fresh RPMI complete medium and flasks were placed in bottom 
position. Cells were counted and split every second day to keep the cell density at 2 × 106 
cells/ml. After 1 week feeders were died leaving the cell line in culture. Cells were re-
analysed for NGFR expression and resorted if necessary. Cell lines were propagated further 
for at least 3 months in culture and sufficient aliquots were stored at different passages. . 
 
 
Statistical Analysis 
All data analyses and respective graphs were drawn by graph pad prism 5. In all cases data 
with p<0.05 was taken as significant.  
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Results 
Identification of the genes and factors potentially involved in CD8+ T cell mediated non-
cytolytic antiviral response (CNAR) is still unsolved. To this end, the aim of our study was to 
focus on the discovery of novel genes and on the elucidation of their biological functions 
contributing to CNAR activity by using SIV-infected macaques as animal model. 
3.1 Characterization of CNAR+ and CNAR- animals 
11 SIV-infected and 10 non-infected rhesus macaques (Macaca mulatta) of Indian origin 
were selected for the study. In order to identify the CNAR+ and CNAR-animals we performed 
in vitro viral inhibition test at initiation of the study. All SIV-infected animals were long term 
non progressors (LTNP) who were positive for the presence of virus for more than three years 
but were showing no symptoms of AIDS. We expected that most of these LTNP will appear 
to be CNAR+ as it is well known CNAR activity may contribute to long term non progression. 
Another advantage of using LTNP was the fact that LTNP in terms of gene expression pattern 
are similar to non-infected individual as compared to progressors thus making the study more 
accurate.  
In vitro viral inhibition assay was performed with the CD8+ T cells isolated from both SIV 
infected and non-infected animals. CD4+ and CD8+ T cells were isolated by MACS (section 
2.4) and their purity was checked by FACS analysis prior to performing the viral inhibition 
test.For qualitative as well as quantitative analysis of desired cell surface molecules, 
flowcytometry analysis was performed. A flow cytometer works on the principle of 
hydrodynamic focusing and exposure of the cells to one or more laser beams. Scattered light 
is measured by a number of detectors mainly the Forward Scatter (FSC, in line with the light 
beam), Side Scatter (SSC, perpendicular light beam) and several fluorescent detectors.  LSR 
II Flow cytometer (BD) was used to check the purity of MACS separated CD4+ and CD8+ T 
cells.More than 90% of the single cells were positive for the respective CD4+ or CD8+ 
population. Fig 3.1 represents one of the representative experiments.   
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(A) 
 
(B) 
Fig 3.1: Flow cytometric dot plot to determine the purity of a MACS-separated cell 
population A) degree of purity of CD8+ T cells; B) CD4+ T cells from PBMCs. 
CD4+ T cells, isolated from the uninfected and largely MHC unmatched donor animals were 
activated with ConA to exclude effects due to classical cytolytic activity. After 24 hours cells 
were infected with SIVmac239. They were either cultured alone as controls (control wells) or 
with ConA activated CD8+ T cells from experimental animals (experimental wells). 
Supernatants were collected at day 5 and 7 for viral RNA quantification.  All CD8+ T cells 
were tested with CD4+ T cells from a reference monkey (2163) to obtain some level of 
standardisation since the susceptibility to the CNAR activity might differ between monkeys. 
At day 5 and 7, viral RNA was isolated from the culture supernatants and quantified by RT 
qPCR. The extent of viral replication inhibition was calculated as the ratio of the viral 
copies/ml in culture supernatants from control wells to the viral copies/ml from the 
experimental wells. CD8+ T cells from each animal were tested with CD4+ cells from at least 
3 different donor animals. If the CD8+ T cells inhibited SIV-replication more than 50fold in at 
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least three independent assays, the animal was categorised as CNAR+ and vice versa (Table 
3.1).  
Table 3.1: Animal Grouping on the Basis Of Viral Inhibition Test* 
SIV-infected (LTNP) N=11  Non infected  N=10 
CNAR+ CNAR- CNAR+ CNAR- 
N=6 N=5 N=4 N=6 
2151*  12535 2247 2163 
2155* 12543  2338* 2272 
2153* 9794 2328* 2324* 
2139* 2219* 2290* 2251* 
2172* 12672   2249 
12671    2278 
* Monkeys marked with an asterisk are related (sibs or half-sibs) 
CNAR+ animals were able to supress the viral replication between 50 to 3000fold in at least 
three independent experiments as compared to CNAR- monkeys where suppression was less 
than 50fold (Fig 3.2). Most of the animals that were found to be CNAR+ were descendants of 
same parental lineage (siblings) and were therefore over represented among the LTNPs. Thus 
it appears as if the CNAR activity is partially an inherited trait. Furthermore it is observed that 
CNAR+ animals were able to suppress the viral replication in vivo and had very low viral load 
as compared to CNAR- animals Fig 3.3. Two animals (12672, 12536) were found to be 
CNAR+ at the start of study but later on (after a year) became CNAR-. This decrease in their 
CNAR activity preceded an increase in viral load. Therefore it is difficult to say if the 
emergence of virus is solely due to loss in CNAR activity or vice versa. Other animals (listed 
as CNAR+) were quite stable towards this activity even over a period of 2 years.  
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Fig 3.2: Fold suppression of SIV replication by CD8+ cells from CNAR+ and CNAR- animals 
from SIV-infected and non-infected monkeys. Each dot represents an independent viral 
inhibition test. 
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Fig 3.3: Viral load of CNAR+ and CNAR- long term non progressors over a period of 189wpi. 
 
3.2 Microarray expression analysis 
Microarray analysis was performed previously with the CD8+ T cells that were re isolated at 
D7 of viral inhibition test. This allowed us to directly identify the genes that were 
differentially expressed in CD8+ T cells of CNAR+ animals as compared to CNAR- animals. 
Global gene expression analysis were applied (DNA Microarray and Deep-Sequencing 
Facility, Göttingen) using the new Macaque 4x44K Design Array (AMADID 015421) from 
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Agilent Technologies, which was generated in collaboration with the University of 
Washington (Katze laboratory). The conceptual design of the study not only enabled us to 
compare CNAR-producing (CNAR+) from CNAR-non-producing (CNAR-) animals but also 
allowed us to compare SIV-infected from uninfected animals (Fig 3.4). 
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Fig 3.4: Heat Map of the microarrays performed with the CD8+ T cells for the comparison of 
(A) SIV + vs. SIV- samples(B). CNAR+ vs. CNAR- samples 
Comparison of expression analysis revealed 50 genes to be at least two fold deregulated in 
CD8+ T cells from SIV-infected as compared to non-infected animals (Infectivity Markers), 
while 78 genes were at least twofold deregulated in CD8+ T from of CNAR+ as compared to 
CNAR- monkeys (CNAR markers). Most transcriptomic changes were observed to participate 
in signalling, regulation of transcription, chromatin maintenance, cell cycle, apoptosis, 
immune response, extracellular matrix, cell adhesion, metabolism and transport (Fig 3.5). 
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Fig 3.5: Biological processes as defined by the Gene Ontology consortium for 
significantlychanged genes. Numbers of genes (%) are shown on the y-axis. 
3.3. Quantitative PCR analysis of selected differentially expressed genes 
16 genes were selected for further validation by real time quantification. (App Table 2 with 
short description of the validated genes) The selection criterion were 
1- Extent of differential expression 
2- Immunological importance of the gene 
3- Relevance with already defined hallmarks of CNAR (protease activity)  
The expression of selected genes was quantified in CD8+ T cells. RNA was isolated from the 
CD8+ T cells of all animals at three different stages 
a) Unstimulated CD8+ T cells right after isolation from PBMCs.  
b) ConA stimulated (D1) of in vitro viral inhibition tests 
c) Co-cultivated and re-isolated at D7 of the in vitro viral inhibition tests 
 All selected genes were quantified by qRT PCR using housekeeping gene GAPDH as 
reference gene. Primers for the validation assays were designed. Efficiency of the primers was 
checked with four fold dilutions of the template in duplicate for each primer pair at different 
temperatures and concentrations. Primers with slope of -3.3 on standard curve of RT-PCR, 
equivalent to 100% efficiency, were selected. 
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∆Ct values were calculated as a difference between the mean Ct values (calculated from the 
duplicates) of each target and reference gene GAPDH  
 
∆ Ct = Mean CT(target gene) - mean CT (GAPDH).  
(A higher ∆Ct values corresponds to lower expression values and vice versa) 
 
For comparison of any of two groups  
∆∆CT was calculated as  
 
∆∆CT= ∆ CT of respective gene in CNAR+ animals - ∆ CT of respective gene in CNAR- 
animals. 
 
For the comparison of SIV-infected and non-infected animals  
∆∆CT= ∆ CT of respective gene in SIV-infected animals - ∆ CT of respective gene in non-
infected  animals. 
 
A higher value of ∆CT will indicate that the respective gene is less expressed in respective 
group and vice versa. Differential expression in all graphs is presented in terms of fold 
changes calculated as  
 
Fold Difference in expression of a gene = 2∆∆Ct 
 
3.4 Comparison of CNAR+ and CNAR- animals 
In our attempts to identify a CNAR-associated gene, relative gene expression was compared 
in CNAR+ and CNAR- animals both in SIV-infected and non-infected animals.  
Upon 7-day co-culture of CD8+ T cells with SIV-infected CD4+ T cells, 7 out of 16 genes, 
namely TNFSF-13B, CST6, Chymase, GSTO1, PRSSL1, FAM26F, and CISH, were found to 
be more than 2 fold up regulated in CNAR- animals as compared to CNAR+ animals in SIV-
infected group of animals (Fig 3.6A). In non-infected group 4 genes namely RPL13, TNFSF-
13B, CST6, and FAM26F were found to up-regulated in CNAR- animals (Fig 3.6B). 
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Fig 3.6: Fold difference in mRNA expression of selected genes in (A) SIV-infected (B) Un-
infected CNAR- animals as compared to CNAR+ animals.  
 
This data showed that only three genes namely TNFSF-13B, CST6, and FAM26F were more 
than twofold deregulated in both SIV-infected and non-infected group of animals. Only 
FAM26F was significantly upregulated in CNAR- animals in comparison to CNAR+ animals, 
both in SIV-infected and non-infected groups (Fig 3.6C). 
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Fig 3.6C: Relative gene expression of FAM26F, CST6 and TNFSF-13B in CD8+ T 
cells from the SIV-infected and non-infected animals. The difference in expression of 
FAM26F between CNAR+ and CNAR- animals is significant in both groups. ∆ Ct was 
calculated as Mean CT (target gene) - mean CT (GAPDH) so a higher ∆Ct values corresponds 
to lower expression and vice versa) 
 
To investigate whether the observed difference in the gene expression was due to ConA-
stimulation or it was the result of co-cultivation during virus inhibition test, we compared the 
mRNA levels of the candidate genes in CD8+ T cells directly after ConA-stimulation (D1) 
between CNAR- and CNAR+ animals. RNA levels of CST6 and FAM26F were more than two 
fold deregulated in infected group, while CST6, Chymase, MMP25, PRSSL1 and PON3 
infected Un-infected infected Un-infected 
infected Un-infected 
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differed more than twofold in non-infected animals but none of the differences were 
significant (Fig 3.7A). 
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Fig 3.7A: Fold difference in mRNA expression of ConA stimulated CD8+ T cells from 
CNAR- animals as compared to CNAR+ animals in both SIV-infected and non-infected 
groups. None of the gene was found to be significantly differentially regulated in both groups 
after ConA stimulation. 
Next it was investigated whether and how gene expression in CD8+  Tcells changes upon co-
culture with SIV-infected CD4+ T cells. Therefore the ∆CT values obtained after co-culture 
were compared with those obtained after ConA-stimulation, because the CT-value of the 
reference gene GAPDH values did not change upon co-culture. Although many genes were 
deregulated upon co-culture only the regulation of FAM26F expression resulted in a 
significant difference between CNAR+ and CNAR- monkeys. As clear from Fig 16B, co-
cultivation of CD8+ T cells with SIV infected CD4 T cells has led to an increase in FAM26F 
expression.  In case of CNAR+ animals this difference was 2.69 in co-cultured samples as 
compared to ConA stimulated samples while in case of CNAR- samples this difference was 
6,48fold. This emphasises that differential FAM26F expression in CNAR+ vs CNAR- animals 
was a consequence of differential up regulation of FAM26F upon co-cultivation (Fig 
3.7B).We further investigated if the selected genes were differentially expressed in CNAR+ 
and CNAR- animals intrinsically. For this purpose, mRNA expression levels of selected genes 
were measured by qRT-PCR directly after isolation CD8+ T cells from PBMCs. None of them 
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was significantly differentially expressed in CNAR+ vs. CNAR-, in both SIV-infected and 
non-infected animals Fig 3.8.  
 
Fig 3.7B: Relative gene expression of FAM26F in CD8+ T cells from CNAR+ and 
CNAR- animals before and after co-cultivation with SIV-infected CD4+ T cells. T test was 
applied to calculate the significance.  ∆Ct was calculated as Mean CT (target gene) - mean CT 
(GAPDH) so a higher ∆Ct values corresponds to lower expression and vice versa) 
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Fig 3.8: Fold difference in the expression of genes in un-stimulated CD8+ T cells from 
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CNAR+ and CNAR- animals in SIV-infected and non-infected animals 
3.5 Comparison of gene expression in CD8+ T cells between SIV-infected 
and non-infected animals  
In order to find the markers of SIV-infection, gene expression level were also 
compared between SIV-infected and non-infected animals irrespective of their CNAR activity 
in CD8+ T cells directly isolated from PBMC (Fig 3.9A) 
 
∆∆ Ct= ∆Ct of respective gene in CNAR+ animals - ∆Ct of respective gene in CNAR- 
animals. 
 
3 genes SLAMF8, CHYMASE, and PRSSL1 were found to be significantly down-regulated 
while TNFSF-13B and EPHB were found to significantly up-nregulated in SIV-infected 
animals as compared to non-infected macaques (Fig 3.9B).  
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Fig 3.9A: Fold difference in gene expression of non-infected animals as compared to the SIV-
infected animals. 
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Fig 3.9B:∆CTof genes that were found to be significantly differentially expressed (T 
test applied) in SIV-infected animals as compared to non-infected animals. . ∆ Ct was 
calculated as Mean CT (target gene) - mean CT (GAPDH) so a higher ∆Ct values corresponds 
to lower expression and vice versa) 
  
 
After finding FAM26F as sole differentially expressed between CNAR+ vs CNAR- for our 
further investigation we focussed on following aspects 
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• Genetic studies of FAM26F 
• Regulation of FAM26F during course of immunisation and infection in two 
independent vaccine experiments. 
• Correlation of FAM26F with viral load. 
• Correlation of FAM26F with other important genes of immune system (Mx1, IP-10, 
tetherin). 
• Establishment of permanent T cell lines to obtain sufficient standardized material for 
further investigations into non-cytolytic antiviral activity. 
 
3.6 Genetic Studies of FAM26F 
In order to investigate if CAF activity can be related to genetic differences in FAM26F gene, 
cDNA sequence of FAM26F was cloned and sequenced from our previously characterized 
CNAR+ and CNAR- group of animals. FAM26F cDNA was amplified from each of the four 
groups (SIV-infected CAF+ and CAF-, non-infected CAF+ and CAF-) (Fig 3.10) and amplified 
fragment was then cloned and sequenced as described in section 2.13. 
 
 
 Fig 3.10: Electropherogram of ethidium bromide stained 1% agarose gel showing PCR 
amplified FAM26F cDNA products in 12 selected animals.971bp FAM26F fragment along 
with DNA ladder.  
 
 
Chromatograms were analyzed by Bioedit software. The sequences were aligned and 
compared with Macaca mulatta FAM26F sequence (Genbank accession number 
XM_001111520) (Fig 3.11). We were able to identify two alleles on the basis of nucleotide 
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difference at position c.208 and c.805 of FAM26F gene (Table 3.2). Nucleotide change at 
position 208 does not lead to a change in amino acid sequence whereas nucleotide change at 
position 805 is indicating a change of Lys to Glu amino acid.  
Majority of animals (10) were heterozygotes for these two alleles. Only two were 
homozygotes for allele B and both were CNAR+. Tendency for over-representation of allele B 
in CAF+ animals was regarded as a reason for further investigations. It may be possible that 
polymorphism have an influence on survival time or viral load at set-point in SIV-infected 
macaques. Therefore, polymorphism typing was initiated in a larger sample of about 170 SIV-
infected macaques using Taqman-based genotyping assay. Primers and probes were designed 
by TIB Molbiol synthesis-lab but the assays were not able to discriminate the polymorphisms 
probably of high GC regions of FAM26F.   
 
 
 
 
 
 
Table 3.2: Alleles identified after sequencing of FAM26F cDNA clones from selected 
CNAR+ and CNAR- animals.  
 
 
 
 
 
 
 
 
 Position c.208 Position c.805 
Reference allele  C A 
Allele A T A 
Allele B T G 


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Fig 3.11: FAM26Fsequence alignment with the Genbank FAM26F sequence 
(XM_001111520).  
 
3.7 FAM26F regulation during course of infection 
In order to investigate a possible connection of FAM26F with viral load and other immune 
components, we undertook a cross-sectional study. Total RNA isolated from whole blood 
(section 2.8) of SIV-infected rhesus macaque, 24 weeks after infection, was quantified using 
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Genbank 
accession number CO774281) as reference. All samples were run at least in duplicates. The 
results were analysed by Sequence Detection Software (ABI) and ∆Ct of FAM26F were 
plotted against respective viral loads (Fig 3.12). 
 
Fig 3.12: ∆CT of FAM26F relative to GAPDH plotted against log viral load. Data shows a 
direct correlation of FAM26F expression with viral load in selected animals (p= 0.0202). 
A significant (p=0.0202) correlation was found when viral load was plotted against ∆CT and 
data was analysed by two-tailed spearman correlation. In other words FAM26F expression 
seems to be associated with viral load and can be further investigated as a potential marker of 
infection. This investigation was extended to more animals in longitudinal studies. To find out 
expression variation of FAM26F upon infection and immunisation and its correlation with 
some other well-known genes of immune components, samples from two independent vaccine 
experiments were investigated.  
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The first experiment (Exp-1) included 6 control (non-vaccinated) and 12 vaccinated animals 
that were studied before and after SIV infection. The monkeys have been infected by a so-
called repeated low dose challenge that is supposed to depict the “natural” infection more 
closely than a single high dose challenge. Macaques from experiment 1 were challenged 
weekly intrarectally with escalating doses of SIVmac251 (30 TCID50 up to 7 times and 60 
TCID50 up to 8 times) until they became productively infected (viral RNA copies >50/ml 
plasma). Blood for RNA quantification was drawn at the day of the third, fourth and fifth 
challenge, therefore these data may not represent true pre-infection values.  After infection 
blood samples were also collected at indicated time points Fig 3.13. 
Second group (Exp-2) included 24 animals and both immunization and infection studies were 
performed. Animals were challenged intra rectally with 120 TCID50 of SIVmac251 up to 8 
times until they became productively infected (viral RNA copies >50/ml plasma). Blood for 
RNA quantification was drawn at the day before the first inoculation of SIV. After infection 
blood additionally was drawn at the indicated time points (Fig.13).  
 
 
 
 
   
 
 
 
Fig 3.13 : Time lines for the (A) Experiment 1 (B) Experiment 2 indicating the time points  
when blood samples were taken for quantification of specified genes. Pre inf stand for pre 
infection, PI for pre immunization, FP for 24hrs and 48hrs after a final priming, Boost 24hrs 
and 48hrs after boosting (final vaccination), DOI for Day of first challenge and wpi for weeks 
post infection. 
To simplify the interpretation of data, ∆ CT was calculated as  
∆ Ct = mean CT (GAPDH) - Mean CT (target gene)    
 Pre inf 
 !  
! !"  !"  
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This implies that a higher value of ∆ Ct represents the higher expression and vice 
versa (unlike the ∆ Ct calculations made in data sets mentioned earlier)  
 
3.7.1 Gene expression variations after infection: 
In both experiments FAM26F expression was quantified at the specified time points (Fig 
3.13) along with Mx1, IP-10 and tetherin. These genes are well documented for their 
importance in innate immunity with respect to viral load or/and immune activation or 
SIV/HIV restriction. All genes under investigation follow almost same expression pattern 
with only minor fluctuations. All of them were significantly upregulated after infection as 
compared to their pre infection expression values. Mx1 showed highest expression 1wpi 
compared to IP-10, FAM26F and tetherin. 12 wpi Mx1 expression increased on average 3fold 
in Exp1 and 16fold in Exp2. For IP-10, tetherin and FAM26F this induction was 4.7, 1.6 and 
2.2folds respectively. (Fig: 3.14). This increased expression of genes upon infection is 
maintained after 48 weeks post infection in experiment 1 for all genes except for tetherin, 
where difference was significant till 24 weeks post infection. The importance of Mx1, IP-10 
and tetherin in innate immunity is well known (references). Our data suggests that expression 
pattern of FAM26F after infection is similar to above mentioned genes so these findings may 
suggest a role of FAM26F in innate immunity. It should also be noted that the expression of 
the investigated genes at pre-infection levels were different among animals in both vaccine 
groups. Furthermore, there were large interindiviudal differences in expression before 
infection (e.g. for Mx1 16fold,). However, except for FAM26F these differences did not 
correlate with viral load after infection (see below). 
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(D) 
Fig 3.14: Expression variations of (A) Mx1 (B) IP-10 (C) Tetherin (D) FAM26F during 
course of SIV infection in two independent experiments.A higher Ct values correspond to 
higher gene expression values. 
3.7.2 Correlation of gene expression with viral load 
We were interested to know whether the expression of the genes under investigation is 
correlated to the viral load at respective time point. In both experiments Mx1, IP-10 
expression were significantly positively correlated with the viral load (Fig 3.15 A, B) (For 
simplicity only 24wpi data is shown) as described by others [203]. 
For the first time a significant correlation between tetherin expression and respective viral 
load was found (Fig 3.15C). In contrast, FAM26F was not found to be correlated with viral 
load (Fig 3.15D). 
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Fig 3.15:Correlation of (A) Mx1 (B) IP-10 (C) tetherin (D) FAM26F gene expression levels 
(∆CT) with viral load at week 24 post infection. P values are indicated. ∆CT was calculated as 
mean CT (GAPDH) - Mean CT (target gene) so that higher Ct values correspond to higher 
expression values 
 
3.7.3 FAM26F – an early predictor of viral load 
In both vaccine experiments we also studied whether expression of FAM26F may be an early 
predictor/indicator of viral load during the chronic phase of infection. In experiment 1, 
FAM26F expression 2 weeks post infection was found to be positively correlated with plasma 
viral RNA copies at 12, 24 and 48 wpi (Fig 3.16). Unfortunately this could not be validated 
with data from exp. 2 because from this experiment, 2 wpi samples were not available. 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.16: Significant correlation of 2wpi FAM26F expression with (A) viral load 2wpi (B) 
viral load 12wpi (C) viral load 24wpi. P values are indicated in boxes. ∆CT was calculated 
mean CT (GAPDH) - Mean CT (target gene) so that higher Ct values correspond to higher 
expression values 
 
Next it was calculated whether the pre-infection levels of any of the studied genes are 
correlated to set point viral load. In both experiments, pre infection values of Mx1, IP-10 and 
tetherin were not correlated with set point viral load. Interestingly, in experiment- 2, pre-
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infection values of FAM26F were inversely correlated with viral load 2, 12 and 24 wpi (Fig 
3.17 A). This suggests FAM26F as an indicator of chronic phase viral load. However this was 
not the case for Exp. 1 (Fig: 3.17 B) possibly because of two outliers. Furthermore, one has to 
keep in mind that the blood samples for Exp. 1 were drawn after the animals had been 
inoculated with virus.  
Interestingly, the pre infection values were positively correlated with the viral load at set 
point, while the post infection values (wpi 2, Exp. 2) were inversely correlated with viral load 
at set point like Mx1 and IP-10. 
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Fig 3.17: Correlation of pre infection expression of FAM26F with viral load 2, 12 and 24wpi 
in (A) experiment1 (B) experiment 2. P values are shown in boxes.  ∆CT was calculated mean 
CT (GAPDH) - Mean CT (target gene) so that higher Ct values correspond to higher 
expression values 
 
3.8 FAM26F regulation during course of immunization 
Exp-1 it was investigated whether the expression levels of genes belonging to the innate 
immunity (Mx1, IP-10), a viral restriction factor (tetherin) and FAM26F varied during 
immunisation, and whether this variation may be related to vaccine efficacy. Briefly, the 
immunisation procedure followed a prime-boost strategy and included at first two injections 
of single-cycle immunodeficiency viruses within a four-week interval [204].Thereafter the 
monkeys were split in two groups of 6 animals. Group A received two times an adenovirus-
derived vector expressing SIV genes via the tonsils [205] followed by an intramuscular 
immunisation with a fowlpox virus-derived vector expressing SIV genes [206]. Group B 
received two times a fowlpox virus-derived vector expressing SIV-genes via the tonsils 
followed by an intramuscular immunisation with the adenovirus-derived vector expressing 
SIV-genes. Thus group A was primed with an adenovirus-derived vector followed by a boost 
with a fowlpox virus-derived vector, whereas the procedure for group B was vice versa. For 
each vaccine group, 3 “control” animals were “immunised” with so-called empty vectors. 
These controls are important as the virus-derived vectors may also stimulate innate immunity 
and may confer some level of protection. 
 Blood samples for RNA quantification were drawn before initiation of the immunisation 
procedure, 24 and 48 hours after immunisation for the final prime (fowlpox virus vector 
constructs via the tonsil or adenovirus vector constructs via the tonsils), the boost (adenovirus 
vector or fowlpox virus vector intramuscular) and at the day of first challenge with SIV (see 
above). 
Expression of all the genes under investigation showed non-uniform fluctuations upon final 
priming as compared to pre immunization values (Fig 3.18). These changes were partially 
independent of SIV-vaccines as the empty vector control groups also showed such 
fluctuations. However, the final boosting resulted in marked differences between the 
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

twogroups. Notably boosting resulted in an increase in expression of Mx1 in both groups. 
This enhanced expression was persistent till 48 hrs only in group 1 (Fig 3.18 A) whereas it 
dropped rapidly in group 2. Although the difference in expression of Mx1 between both 
vaccinegroups was not significant 48 h after boosting, it was significant at the day of 1st 
challenge (pre infection) Fig 3.19 
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Fig 3.18:  Expression variations of (A) Mx1 (B) IP-10 (C) tetherin (D) FAM26F before 
(PRE-IMMU), during course of immunization in two vaccine experiments, and at the day of 
challenge (DOC)(C: controls and V: vaccinees). For comparison of FAM26F pre-
immunization and day of challenge values a new batch of primers (NP)  had to be used∆CT 
was calculated mean CT (GAPDH) - Mean CT (target gene)so that higher Ct values correspond 
to higher expression values. 
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In contrast, IP-10, tetherin and FAM26F upregulation was delayed and more variable in group 
1 compared to group 2 where the expression of these genes peaked 24 hrs post immunisation. 
The difference of IP-10, FAM26F and tetherin expression after 24hrs of boosting is 
significantly different between both vaccine groups Fig 3.19 (B, C, D and E). Furthermore, 
tetherin and FAM26F expression were even significantly enhanced 48 hrs post immunisation 
in group 2 compared to group 1 (Fig. 3.19). 
Notably, the results show that FAM26F is as fast deregulated as the other components of the 
innate immune system (Mx1, IP-10), this also emphasises our observation of infection study 
suggesting FAM26F as an important player of innate immunity. 
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Fig 3.19: Significant differences of gene expression between group 1 (GP1) and group 2 
(GP2) after immunization that was attributed to protection and vaccine efficacy in group 
2.∆CT was calculated mean CT (GAPDH) - Mean CT (target gene) so that higher Ct values 
correspond to higher expression values. 
In the light of above mentioned analysis, we can say that different immunisation procedure 
had certainly different effects (statistically significant) on the innate immune 
response/activation. Interestingly this relates with the difference in set point viral load after 
infection of animals. In group 2 animals had lower viral load and greater protection against 
infection as compared to group 1 (Fig 3.20A). Moreover, numbers of challenges to infect the 
animals in group 2 were more than to infect the animals in group 1 (Fig 3.20B). It seems as if 
a different pattern in activation of components of the innate immune system (e.g. increased 
expression of IP-10, FAM26F and tetherin after boosting) has resulted in observed lower viral 
load and increased level of protection in group 2. It is also important to note that all the 
significant differences were only in vaccinees and not in control groups. 
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Fig 3.20A: Viral load of three infected groups over time of 41wpi. 
 
 
 
 
 
 
 
 
Fig 3.20B: Fraction of uninfected animals in controls and both vaccine groups during the 
course of challenge.  
 
 
3.9 FAM26F correlation with other immune components  
Furthermore the expression of FAM26F and its correlation with the expression of other genes 
(Mx1, IP-10, tetherin) was also investigated.  FAM26F was significantly correlated with all 
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three genes under investigation Mx1, IP- and tetherin in both independent experiments (Fig 
3.21). However its strongest correlation was found with IP-10. These observations were 
further confirmed by in vitro experiments (see below).  
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Fig 3.21: Correlation of FAM26F with (A) Mx1 (B) IP-10 and (C) tetherin RNA levels in 
PBMCs from two independent vaccine experiments. 
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3.10 Expression of FAM26F in different lymphocyte populations: 
FAM26F expression was quantified by qRT-PCR in different cell populations including 
CD8+, CD4+ and CD20+ (B cells) along with Mx1, tetherin, and IP-10 in 4 animals.  Results 
are expressed as copies per 100 copies GAPDH using following formula(Pfaffl, 2001) 
Copies per 100 copies of GAPDH (rE) = 1/(2 ∆Ct) * 100 
Maximum expression of FAM26F was observed in CD4 cells. Mx1 and IP10 were highly 
expressed in CD20 while highest levels of tetherin were found in CD8 + T cells (Fig3.22).  
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Fig 3.22: Expression of FAM26F in different cell types in four independent experiments. 
3.11 In vitro activation studies of FAM26F 
In order to investigate the effect of Interferon alpha (INF-alpha), Interferon gamma (INF-
gamma) and Tumor necrosis factor alpha (TNF-alpha) stimulation on the expression of 
FAM26F, in vitro PBMC stimulation experiments were performed as described in 2.14. RNA 
expression was measured after 6, 12, 24 and 48 hours after stimulation. ∆ Ct was calculated as 
follows 
∆ CT= Mean CT (target gene) - mean CT (GAPDH).  
∆∆CT was calculated as  
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∆∆CT= ∆CTof candidate gene in interferon stimulated samples - ∆CT of respective gene in control 
samples. 
Differential expression in all graphs is presented in terms of Fold changes calculated as  
 
Fold change = 2∆∆CT 
Interferon Alpha stimulation resulted in 100fold increase in Mx1 expression, as expected 
since Mx1 is an interferon alpha regulated gene. IP-10 was 13fold while tetherin and 
FAM26F were increased 4fold and 12 fold respectively after interferon alpha stimulation. 
Expressions of all genes under investigation increased 6 hours post stimulation. Tetherin and 
FAM26F levels continued to increase and reached their maximum levels 12 hours post 
stimulation. IP-10 levels started to decline 6 hrs post stimulation while Mx1 levels declined 
after 12 hours (Fig 3.23A).  
 
 
 
 
 
 
 
Fig 3.23A:  Changes in the expression pattern of selected genes after 100ng of Interferon-
alpha (INF-α) stimulation in three independent experiments.  
Interferon Gamma stimulation resulted in maximum increase in FAM26F expression as 
compared to Mx1, IP-10 and tetherin. Expression of all the genes under investigation 
increased 6 hours post stimulation and returned to baseline 48 hours post stimulation (Fig 
3.23B). 
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Fig 3.23B:  Changes in the expression pattern of selected genes after 10ng of Interferon-
gamma (INF-γ) stimulation in three independent experiments. 
PBMCs were stimulated with 10, 50 and 100ng of tumor necrosis factor alpha but no 
significant effect in any gene of interest was observed after 6 hours of stimulation (3.23C). 
Further investigations were therefore dismissed. 
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Fig 3.23C:  Changes in the expression pattern of selected genes after 10, 50 and 100ng of 
Tumor necrosis factor-alpha (TNF-α) stimulationafter 6 hours of stimulation 
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3.12 Establishment of permanent monkey T cell lines. 
After confirming the differential expression of FAM26F by Real time quantification, we 
planned to continue further investigations of this membrane bound protein with FACS 
analysis or Western Blot. But unfortunately till date no antibody against FAM26F for rhesus 
macaques (Macaca mulatta) is available. Shortage and lack of standardized material is a key 
drawback when working with primary cells, especially from monkeys. A study stating that 
noncytotoxic suppression of human immunodeficiency virus type1 transcription is possibly 
mediated by exosomes secreted from CD8+T cells[150].We wanted to investigate the 
differential protein expression in exosomes secreted by CD8+T cells of our CNAR+ and CAF- 
groups. For such type of studies there was a demand to establish immortal CD8+ T cell lines, 
as material from primary cells is not enough for such type of study. So we decided to establish 
these CD8+ T cell lines from our already characterized CNAR+ and CNAR- group of 
animals.The insertion of oncogenes to immortalize various mammalian cell types [207] had 
resulted in altered cellular signalling pathways and a loss of normal cell-cycle functions [208]. 
Telomerase expression vectors, used to immortalize normal human fibroblast and epithelial 
cells have been proven a better option in this regard [209]. The ability of human telomerase 
reverse transcriptase (hTERT) to extend cellular proliferative capacity by stabilizing the 
telomere length is well documented. Many cell types immortalized by hTERT did not indicate 
cancer-associated changes and show normal cellular responses to DNA damage signals [210]. 
We undertook this strategy to establish permanent cell lines for our study. Murine leukaemia 
virus (MuLV)-based retroviral vectors can transduce dividing cells. Infecting cultures of 
antigen-stimulated PBMCs with MuLV-based vectors carrying immortalizing genes, results in 
the selective immortalization of T cells.  
3.12.1 Principle 
The retroviral vectors are widely used to stably integrate the gene of interest in target cells. 
Vector xlox (NGFR) TERT co-expresses the human telomerase gene (hTERT) and a surface 
marker, C-terminally truncated human low-affinity nerve growth factor receptor (NGFR). To 
facilitate the production of high viral vector titers, we used a producer cell line GP2xTERT11 
carrying stably integrated xlox (∆NGFR) TERT vector. Thus to produce the retroviral vector, 
GP2xTERT11 cells are transfected with envelope construct (e.g. RD114). Anti-CD3 
antibody-stimulated T cells are infected with these replication defective retroviral vectors. 
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The transduced cells co-express hTERT and a surface marker, ∆LNGFR, and thus can be 
easily purified by immunomagnetic cell sorting. TERT gene continuously produces 
telomerase resulting in immortalization of transduced cells while preserving the properties of 
primary cells. 
3.12.2 Vector stock preparation and titer determination 
Before starting with the viral vector production, initial optimization of the transfection 
efficiency was done using different concentrations of GFP (green fluorescent protein) 
construct and transfection reagent at various incubation times were tested with GP2xTERT11. 
Optimal transfection efficiency (30%) was obtained with 10µg of plasmid using 22µl of 
TransIt-293 transfection reagent (Fig: 3.24). To produce the viral vectors carrying hTERT 
gene, GP2xTERT11 cells were transfected with RD114 envelope construct and collecting the 
supernatant as described in section 2,15,2.  
Before transducing the target primary T cells, exact titers of viral vector stocks were 
determined by retronectin mediated transduction of C8166 cells.48 hrs post-transduction, 
percentage of NGFR+ cells was determined by FACS analysis as described in section 2,15,4. 
Non-transduced C8166 cells were used as negative controls for FACS analysis. On the basis 
of % positive cells, the viral titers were calculated as follows:  
 Number of viral vector particles = Number of cells initially plated × % of LNGFR+ cells. 
For most of viral vector preparations titers were in range of 5-9 × 105 viruses/ml 
              
(3.24A)                           (3.24B) 
Fig 3.24:  GFP transfected GP2xTERT11 producer cell line (A) 24 hours post transfection (B) 
36 hours post transfection.   
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   (3.25A)                                                                (3.25B) 
Fig 3.25: FACS analysis of C8166 cells (A) non-transduced C8166 cells as negative control 
(2B) C8166 cells transduced with undiluted viral vector stock. 79.2% cells were LNGFR+ 
which is equivalent to 7.9 × 105 viral vector particles/ml.  
3.12.3 Activation of target primary T cells:  
 In our initial experiments Concanavalin-A (ConA) was used to activate the target primary T-
Cells. But we were not able to get the desired transduction efficiency with ConA as a T cell 
stimulant. It was found that ConA activation leads to increased cell death (52.7% dead cells)  
as compared to plate bound anti CD3  antibody (4.98 % dead cells) (Fig 3,26A, B). This gave 
us an explanation of lower than the expected transduction efficiency. Latter on use of plate 
bound anti CD3 antibody in subsequent experiments lead us to improved transduction rate. 
With ConA stimulation, 25.1% and 21.3% CD69+-HLA-DR+ double positive cells were found 
on CD4+ and CD8+ cells populations respectively (Fig 3.26C, D). While 10.7% and 17.5% 
double positive cells were found on CD4+  and CD8+  cells respectively with anti CD3 
activation (Fig 3.26E, 3.26F), indicating a slight difference in the activation markers CD69 
and HLA-DR in both activations. This difference is most likely not affecting the CAF activity 
as anti CD3 antibody stimulation is used by others for viral inhibition assays [6]. 
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(3.26A)            (3.26B) 
Fig 3.26:  Percentage of live/dead cells, after 48 hours activation of PBMC activation with 
(A) plate bound anti CD3 antibody (B) Concanavalin-A.  
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(3.26C)          (3.26D) 
Fig 3.26: Percentage ofCD69-HLADR double positive cells on CD4+ cells (C) CD8+ cells (D) 
after Concanavalin-A stimulation.  
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(3.26E)       (3.26F) 
Fig 3.26: Percentage ofCD69-HLA-DR double positive cells on CD4+ cells (E) CD8+ cells (F) 
after plate bound anti CD3 antibody stimulation.  
3.12.4 Transduction of target primary T-cells 
Blood was drawn from the target animal and CD4+ T cells or CD8+ T cells were isolated from 
the PBMC (section 2.2 and 2.3). Cells were activated by plate bound anti CD3 antibody 
(section 2.15.3) and transduced with the retroviral vector stocks whose titers were above   5 × 
105 as described in section 2.15.4. Transduction efficiency of target primary T cells varied 
from 6-27%. We are able to get maximum of 27.5% transduction efficiency for CD4 cells and 
23.9% for CD8 cells (Fig: 7B, 7C). LNGFR+ cells were sorted by (MACS) and were cultured 
along with feeders as described in section 2,15,5. 
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(3.27C) 
Fig 3.27: FACS histograms of transduced NGFR+ (A) C8166 positive control of transduction 
(B) Target primary CD4+T cells (C) Target primary CD8+ T cells. Red-lined histograms 
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indicate the non-transduced negative controls while blue-lined histograms are representatives 
of transduced cells.    
3.12.5 Post transduction culturing 
Once the transduced NGFR+ cells were purified by (MACS), they were co-cultured with 
feeder cells. Cells were counted and split every second day. Cells were re-analysed for NGFR 
expression after every 3 days and In several experiments, the number of NGFR+ cells 
increased (Fig: 3.28 representative of 1 experiment). We were successfully able to establish a 
CD4+ T cell line that was propagated further for at least 3 months in culture and sufficient 
aliquots were stored at different passages. This cell line is in culture for more than 1 year now. 
Expression of different surface markers was analysed by FACS (fig 3.29). Although we were 
able to efficiently transduce the CD8+ T cells and LNGFR expression was more than 90% at 
d9 (fig 3.28) these cells showed a problem with the post culturing and were not able to 
survive in culture for more than 3 weeks. 
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Fig 3.28:FACS dot plots of CD8+ T cells showing percentages of  LNGFR+ cells in (A) 
controls (B) Transduced d1 (C) d3 of culture (D) d6 of culture (E) d9 of culture.
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3.12.6 FACS analysis of CD4 cell line 
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Fig 3.29:FACS chromatograms of CD4+ T cell line showing expression of different cell 
surface markers. 
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Discussion 
HIV infection usually results in a progressive immunodeficiency disease culminating in the 
development of AIDS however a small subset of infected individuals, known as elite 
controllers has been described to escape disease progression for prolonged periods. Strong 
immune responses and low virus loads in these individuals [211] raise the possibility that 
specific and/or particularly effective antiviral immune responses may confer long-lasting 
protection.   
In addition to their MHC class I-restricted antigen-specific anti-HIV-1 CTL effector function, 
noncytolytic suppression of HIV-1 via secretion of soluble factors (CNAR) has also been 
described for more than 2 decades. It is now apparent from the results of many laboratories 
that CD8+ T cells from asymptomatic infected individuals can potently inhibit HIV-1 
replication through noncytolytic mechanisms. However, the nature of this inhibitory activity 
has not been discovered yet and its role as a component of protective immunity has remained 
controversial. 
To this end our study focused on the identification of these factors responsible for 
noncytolytic viral suppression of virus. For this purpose SIV-infected rhesus macaques were 
used as animal models. At first in vitro viral inhibition tests were performed to identify 
CNAR+ and CNAR- animals. Notably, CNAR activity of the CD8+ T cells was tested not only 
from SIV-infected long term non- progressors (LTNPs) but also from the non-infected 
animals. So for the first time it was shown that CD8+ T cells of the non-infected animals can 
display CNAR activity. However, the extent of inhibition is lower in non-infected than in 
SIV-infected monkeys.  
We also observed that CNAR+ LTNPs had on average a lower in vivo viral load as compared 
to CNAR- LTNPs. This observation is in line with the observation made in HIV-infected 
humans where an inverse relation between the extent of this CD8 non cytolytic antiviral 
response and level of plasma viraemia was documented [138].  
It is well documented that a decrease in CNAR activity is found to be associated with increase 
viral load and disease progression in HIV-infected humans [128]. Similar results were found 
in our study where the loss of CNAR activity preceded the increase in viral load of two 
animals (12672, 12536). It is difficult to conclude if the emergence of virus is solely due to 
loss in CNAR activity. Presence of genetically similar animals (half-siblings) in CNAR+ 
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group of LTNPs and noninfected macaques indicated that CNAR activity can partially be an 
inherited trait. 
In order to identify the genes mediating CNAR, differential gene expression between CD8+ T 
cells from CNAR+ and CNAR- monkeys was evaluated from infected as well as non-infected 
groups. This was two pronged strategy that not only allowed us to identify the differentially 
expressed genes among CNAR+ and CNAR- animals but also helped us to find the differential 
gene expression among infected and non-infected CD8+ T cells. Furthermore, this allowed 
double screening for the candidate genes. As few genes were found to be differentially 
regulated in infected groups but only those genes were considered that showed a significant 
differential expression in both infected and non-infected group on animals. Almost 78 genes 
were found to be differentially expressed among CNAR+ and CNAR- animals. They are 
involved in a wide variety of cellular processes including immunity, signaling, metabolism 
and cell cycle etc. 16 genes were selected for further validation by real time qPCR. The 
selection was based not only on the extent of differential expression (>2 fold) but also on the 
immunological importance of the genes and their relevance to the already defined 
characteristics of CAF. For example CAF is reported to have a protease activity as the 
antiviral effect is diminished by protease inhibitors. In our selected genes three members 
(Chymase, PRSSL-1 and MMP25) were proteases in nature and were more than two fold 
differentially regulated in the initial microarray study.  
Evaluating the differential expression of CD8+ T cells at three different levels i.e. un-
stimulated, ConA activated and co-cultivated with infected CD4, helped us to clearly evaluate 
if observed differential expression was intrinsically present in CD8+ T cells of CNAR+ and 
CNAR- animals or if it had emerged during co-cultivation of the cells. The results showed that 
none of the selected genes was differentially expressed after isolation from blood or after 
Con-stimulation.However, after co-culture with SIV-infected cells one gene, namely 
FAM26F, was found to be significantly overexpressed in CNAR- animals as compared to 
CNAR+ animals in both, infected and non-infected group of animals (Fig 3.6C). Since this 
differential expression was not significant in un-stimulated and ConA activated CD8+ T cells, 
FAM26F was up-regulated in CNAR- samples to larger extent than in CNAR+ samples as a 
result of their co-cultivation with CD4+ T cells during viral inhibition test (Fig 3.7B).  
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4.1 Difference between CD8+ T cells from infected and noninfected animals 
As mentioned earlier our microarray study enabled us to identify the genes differentially 
expressed between CD8+ T cells of infected and non-infected animals. 3 genes, namely 
SLAMF8, (signalling lymphocytic activation molecule), the proteinases CHYMASE, and 
PRSSL1 were found to be significantly up regulated while TNFSF13B, and EPHB1 were 
found to significantly down regulated in SIV-infected animals as compared to non-infected 
macaques.  SLAM-related receptors (in presence of SAP adaptors are reported to be involved 
in stimulatory signalling for B cell signalling while in absence of adaptors mediate inhibitory 
signals. Chymase and PRSSL1 are serine proteases and reported to be involved in various 
physiological functions. TNFSF13B is reported to be involved in B cell activation and its 
reduced level has been associated with prolonged time to AIDS in HIV-infected viremic 
patients [212]. Furthermore its expression distinguished pathogenic (rhesus macaque model) 
from non-pathogenic (sooty mangabey model) SIV-infection [212]. EPHB1 is reported to be 
implicated in development of nervous system. Although up-regulation of these genes in 
CD8+T cells from SIV-infected animal seems relevant in this context, further investigations 
will help to clearly define their exact function.  
 
4.2 FAM26F expression after interferon stimulation 
FAM26F was found to be expressed on CD4+ T, CD8+ T and B cells. In vitro stimulation with 
IFN- α induced slight increase in the expression of FAM26F after 6 hrs that diminished 48 hrs 
post stimulation. This increase was much less than the well-known IFN-α stimulated gene 
Mx1 (100fold vs. 12fold respectively). Stimulation with IFN-γ induced FAM26F expression 
greater than all genes under investigation i.e. Mx1, IP-10 and tetherin. IFN-γ mediated 
FAM26F induction was even greater than IP-10 which is a well-known IFN-γ responsive gene 
(12fold vs. 5fold respectively), indicating that FAM26F is an IFN-γ responsive gene. IFN-γ is 
a pro inflammatory cytokine involved in modulation of diverse immune responses. Similar to 
FAM26F it is produced by NK cells, activated CD4 helper cells, CD8+ T and B cells. IFN-γ 
induced responses are very diverse including up regulation of MHC-1, MHC-II, PKR, 
ADAR1, GBPI and 2. IFN-γ elicits also apoptotic functions by upregulating proteins like 
IRF1, caspases, cathepsins, Fas and TNF alpha receptors. Antimicrobial mechanisms involve 
induction of ROS (reactive oxygen species) and many other genes [108]. Most important to 
note are the genes that are involved not in the cytolytic effector function but involved in the 
immunomodulation, Th development and leukocyte trafficking. These include IL-12, 


CXCL10 (IP-10), CXCL9 (MIG), CCL3, CCL4 (MIP1 alpha and beta, RANTES, ICAM-1 
VCAM-1. Most of the above mention members have been previously attributed to be secreted 
by CD8+ T cells or represent membrane proteins and were studied specially in relationship to 
general viral inhibition. This may indicate that FAM26F could play an important role in 
diverse IFN-γ responses, both in innate and adaptive arms of immunity. We have investigated 
FAM26F expression in whole PBMCs; however further studies focusing on the IFN- γ 
mediated FAM26F induction in different subpopulations (e.g. CD4, CD8. NK and B cells) 
will be a step forward to fit it in diverse range of INF - γ functions. 
Identification of FAM26F as a protein that distinguishes CNAR+ and CNAR- animals in the in 
vitro inhibition test, its regulation by IFN-gamma, and expression on major immune cells 
suggest that it plays a role in immunity. These findings lead us to investigate its expression 
pattern during infection and immunization. 
 
4.3 FAM26F expression during infection 
After finding FAM26F correlation with viral load in a small cross sectional study, the 
expression pattern of FAM26F before and after infection was investigated in two independent 
experiments. The monkeys have been infected with SIVmac239 by a so-called repeated low 
dose challenge that is supposed to depict the “natural” infection more closely than a single 
high dose challenge[213].  
Previous studies indicate that an increased expression of innate immune modulators in blood 
and other tissues (e.g. LN and lungs) during acute and chronic SIV infection is correlated with 
viral load. Increased Mx1 mRNA levels in lymphoid tissues [214] and IP-10 (CXCL10) in 
lymph nodes as well as peripheral blood of chronically infected macaques are associated with 
higher viral RNA levels and more rapid disease progression [203]. Similar results were 
observed in our study where expression of innate modulators (e.g. Mx1, IP-10) as well as 
FAM26F was significantly increased after infection. This elevated expression was maintained 
till the end of investigation period in both experiments (48 wpi for Exp1 and 24 wpi for 
Exp2). Furthermore, FAM26F followed same in vivo expression pattern after infection as 
Mx1, IP-10 and tetherin. FAM26F was also found to be significantly correlated with Mx1, IP-
10 and tetherin. Correlation of FAM26F and IP-10 expression was expected because both are 
IFN-γ-regulated/induced genes. All these observations emphasize that FAM26F could also be 
a possible candidate player in immune system, most probably of innate immunity. 
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Results of our study also showed that in both experiments Mx1, and IP-10 were significantly 
correlated with viral load. These results are in agreement with afore mentioned studies for 
Mx1 and IP-10. For the first time a correlation between tetherin and viral load was found in 
our study.  
In contrast, pre infection values of only FAM26F in experiment 2 were inversely correlated 
with 2, 12 and 24 wpi viral load. However this correlation was not significant (although there 
was a trend) in experiment 1 possibly because of two outliers. Furthermore, one has to keep in 
mind that the blood samples for Exp1 were drawn after the animals had been inoculated with 
virus, but did not become infected. In experiment 1, 2 weeks post infection expression of 
FAM26F was found to be positively correlated with plasma viral RNA copies at 12, 24 and 48 
wpi (Fig 16). None of the other genes under investigation showed this correlation. 
Unfortunately this could not be validated with data from experiment 2 because of non-
availability of the samples. Nevertheless, both of these observations indicate that FAM26F 
may be an early predictor/indicator of viral load at set-point during the chronic phase of 
infection and can be considered as early prognostic marker for SIV/HIV infection. Further 
investigations using larger number of animals are required to validate these findings as well as 
samples from HIV-infected humans. 
It should be noted that initially FAM26F expression was found to be correlated with viral load 
in a small cross sectional study. However; the results were not reproduced later on. This could 
be explained by the fact that former study was conducted in a small group of Chinese 
macaques, which have a slower disease course as compared to macaques of Indian origin. 
This sub-species difference may have led to contrasting results.  
 
4.4 FAM26F expression upon immunization 
As explained earlier in section 3.8, immunization study included two groups.  Group 1 was 
primed (final priming) with an adenovirus-derived vector followed by a boost with a fowlpox 
virus-derived vector, whereas the procedure was vice versa for group 2. Control animals for 
each group were “immunized” with so-called empty vectors. 
Expression of already defined surrogate innate immune markers Mx1 and IP-10, a viral 
restriction factor tetherin and new possible candidate of innate immunity, FAM26F were 
studied before immunization, 24 and 48 h after final priming, after the boost and at the day of 
1st challenge. In both groups, expression of all the genes under investigation showed non-
uniform fluctuations upon final priming as compared to pre immunization values (fig. 18). 
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The empty vector control groups also showed such fluctuations indicating that virus-derived 
vectors may also stimulate innate immunity. However, the final boosting resulted in marked 
differences between the two groups.  
For example, expression of Mx1 in group 1 boosted with fowlpox virus-derived vector was 
more variable and more persistent as compared to group 2 boosted with Adenovirus-derived 
vector. In contrast group 2 Mx1 expression was more uniform, peaked 24hrs post boosting 
and declined earlier in comparison to group 1. Thus fowlpox virus-vector induced a stronger 
Mx1/IFN-α response in some animals as compared to boosting with Adenovirus-derived 
vector. In contrast, up-regulation of IP-10, tetherin and FAM26F was more pronounced and 
less divergent in group2 boosted with Adenovirus-derived vector and peaked 24hrs post 
immunisation unlike group 1 boosted with fowlpox-derived vector where it peaked 48hrs post 
immunization. There was a significant difference in elevated expression of IP-10 (24hrs post 
boosting), FAM26F and tetherin (24 hrs and 48hrs post boosting) in vaccinees of group 2 
(Adenovirus-derived vector group) as compared to group1 (fowlpox-derived vector group). 
This difference is notable in the context that group 2 had lower viral load and increased level 
of protection as compared to group1 (Fig 3.19).  
As the expression of Mx1 and tetherin is driven by IFN-α while those of IP-10 and FAM26F 
is induced by IFN-γ, we can extrapolate that both groups differed in terms of level/extent of 
type I and type II responses. The increased level of protection in group 2 can be attributed to 
more pronounced IFN-γ responses or a unique balance between type I and type II responses, 
which may have caused a differential activation of the innate cells and finally to differential 
adaptive immune responses.  
FAM26F expressions pattern during immunization and after SIV-infection similar to Mx1, IP-
10 and tetherin. These observations emphasize the importance of FAM26F in innate immune 
system. FAM26F (family with sequence similarity 26, member F) is member of FAM26 gene 
family. It has been also named as IRF-3–dependent NK-activating molecule (INAM) by 
Tskashi and coworkers [215] . Humans and mouse have 6 members in FAM26 family.  In 
human, 3 members of the family FAM26A/CALHM3, FAM26B/CALHM2, and 
FAM26C/CALHM1 are located on chromosome 10 (19 in mouse), while 3 members 
FAM26D, FAM26E, and  FAM26F/INAM are on chromosome 6 (10 in mouse). In Macaca 
mulatta only 3 members FAM26D, FAM26E, and FAM26F are present on chromosome 
4.[215] 
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Human  FAM26F is a 315 amino acid 34 kD (without phosporylation) protein (in mouse: 40–
55-kD protein with one N-glycosylation site) and possesses four trans-membrane motifs 
aspredicted by the TMHMM Server (version 2.0) (Fig: 4.1) similar to the cell adhesion 
tetraspanins, which may support cell–cell contact (Levy and Shoham, 2005). Alignment of the 
predicted Macaca mulatta and mouse FAM26F amino acid sequence with that of the human 
FAM26F revealed that both shared 88.57 % and 71.7% homology respectively. (Fig: 4.2).  
FAM26F does not have a normal signal peptide as predicted by CBS SignalIP 4.0 prediction 
Server (http://www.cbs.dtu.dk/services/SignalP/). 
 
 
Fig 4.1: Graphic representation of probability of FAM26F transmembrane sequence motifs in 
(A) Homo sapiens (B) Macaca mulatta as predicted by TMHMM Server (version 2.0) . 
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Fig 4.2: Sequence alignment of human, monkey and mouse FAM26F. 
 
Thus it is potentially transported differently to the cell membrane as compared to classical 
endoplasmic reticulum-Golgi route. One suggestive pathway for the proteins that lack signal 
peptide FAM26F (e.g. IL-1β) is via intracellular vesicles. Thus it is possible that FAM26F 
may also be secreted via similar pathways. 
Although exact function and its modulatory pathways are not known for FAM26F, there are a 
lot of studies documenting a role of FAM26F. For example, in an attempt to identify global 
protein responses of IFN-γ and LPS-treated primary human macrophages, FAM26F along 
with several other proteins was identified as activation-specific fingerprint that distinguishes 
primed macrophages from basal (resting) or LPS-activated macrophages [216]. Villitis of 
unknown etiology (VUE) is a destructive inflammatory lesion of villous placenta 
characterized by co-presence of histoincompatible (placental macrophages) and maternal T 
cells leading to placental inflammation. In an attempt to investigate the placental 
transcriptome of VUE, FAM26F was found to one of the most significant up-regulated along 
with several chemokines, MHC class I and class II molecules [217]. 
Another study focusing to identify gene signatures associated with early liver graft failure 
documented FAM26F among top classifier genes along with other genes functionally 
associated with oxidative stress and inflammation [218]. Genome-wide transcriptional profiles 
from the whole blood of patients with septicemic melioidosis (infectious disease caused by 
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the Gramnegative bacillus Burkholderia pseudomallei) identified FAM26F also as a 
differentially expressed gene [219]. In addition, FAM26F was also found to be induced by 
staphylococcal superantigens (SAgs) treatment of PBMCs. [220]. The Atlas database for gene 
expression of unknown genes (Atlas Data or G2SBC database) reports that FAM26F has been 
identified to be differentially expressed in cancer micro-array studies of various organs of the 
human body, including the breast, cervix, mammary  gland,  uterus etc.  [221, 222][221, 223]. 
Song and co-workers associated FAM26F with potential cell growth, proliferation, and 
differentiation during synthetic estrogen analog diethylstilbestrol (DES) induced oviduct 
development in chickens [224]. All these aforementioned studies suggest an important role of 
FAM26F during infection, immunity or cell differentiation. 
So far there is only one publication reporting some insight into the function of FAM26F in 
mice. Takashi and co-workers identified FAM26F as a TLR signal-derived membrane 
molecule that modulates mDC–NK contact-mediated NK activation[215]. They named it 
INAM (IRF-3dependent NK-activating molecule) and showed that it was initially minimally 
expressed on myeloid dendritic (mDC) and NK cells but co-culture of mDCpretreated with 
the TLR3 ligand polyI:C and natural killer (NK) cells resulted in an increased expression of 
FAM26F on both cell types. FAM26F induction was dependent on TICAM-1 and IRF-3 
activation, as TICAM-1-/-or IRF3-/-knockout mDC failed to induce full NK cytotoxicity. They 
further showed that FAM26F contributed to mDC–NK reciprocal activation via its 
cytoplasmic tail, which was crucial for the activation signal in NK cellsbut not for the 
maturation of mDC. The authors suggest furthermore that FAM26F is an IFN type I-inducible 
gene. However, activation of FAM26F results in production of IFN-γ by NK cells. These 
observations do not contradict our study where we showed that invitro IFN-γ and IFN-α 
stimulation of PBMCs resulted in a strong and moderate FAM26F induction, respectively. 
Potentially,these interferons can induce the expression of FAM26F in auto or paracrine 
manner. Thus FAM26F may not only induce IFN-γ production but its expression can be also 
further enhanced by an auto feedback mechanism. Nevertheless, identification of the exact 
signal mechanism will be an issue for further analysis.  
Further studies unfolding the functional aspects of FAM26F will shed more light on the 
relevance of this protein in the whole scenario of immune responses.  
Although it is clear that FAM26F doesn’t fit to the criterion to be a candidate for CAF as its 
properties are different than the CAF (e.g. size and protease activity) and it is higher 
expressed in CNAR- than in CNAR+ animals, it is nevertheless possible that FAM26F acts 
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somewhere intermediate in the mechanism of CAF inhibition. It is possible that virus-infected 
CD4 cells induce the expression of FAM26F expression either directly or indirectly via 
interferons. Our microarray validation by qRT PCR showed that an increased expression of 
FAM26F on CD8+ T cells from CNAR- animals might have resulted in strong viral 
replication. Increased/enhanced levels of FAM26F induced by virus can block the production 
of CAF either at transcription, translational or post translational stage. This inhibition can be 
achieved either directly, via trafficking of other proteins or activating other pathways that in 
turn can inhibit CAF production. In contrast, CD8+ T cells from CNAR+ animals may be able 
to suppress the FAM26F expression by certain unknown mechanisms so that CAF-
inactivation is suppressed. However these mechanisms are too much speculation and our 
hypothesis needs to be confirmed by further experiments. Unfortunately lack of availability of 
antibody against FAM26F has halted further research in this direction. Further studies to find 
the interacting partners of FAM26F will help to understand the function of this protein and its 
relevance in immune system. In summary, our in vitro stimulation as well as infection and 
immunization studies emphasize that FAM26F may be an important regulator of innate or 
adaptive immune response which may indicate an activation state of the immune system.  
FAM26F expression may be an early indicator/marker of the immune status that is especially 
important during primary infection. This could mean that stronger expression of FAM26F 
before infection may indicate an immune status that is able to limit early viral replication, 
whereas a strong increase after infection may indicate already early immune dysregulation 
that is later on associated with higher viral load. In this case FAM26F could be at least 
regarded an early diagnostic marker. 
Irrespective whether FAM26F is involved directly in regulation of viral replication or 
indirectly via the immune defense, our study has shown that it is an important molecule that 
merits further investigation.  
 
4.5 Phenotypic characterization of CD4+ T cells  
Expression of different markers on the surface of CD4 cell line was analyzed by FACS. Cells 
were CD4+, CD8- and highly expressed CD11a, an antigen found on all leukocytes. 
Expression of the leukocyte common antigen CD45 was very low as was the expression of the 
T-cell markers CD3, TCRab, CD27 (none), CD28 and CD45RA. These moleculesare 
normally present on the naïve T cells and their expression is downmodulated afteractivation. 
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Fig 4.3: A hypothetical model for the mode of action of FAM26F. Increased expression of 
FAM26F induced by interferons results in the capture of virus inhibitory molecules/CAF in 
CNAR- cells. CD8+ T cells from CNAR+ animals are able to down regulate the expression of 
FAM26F and are able to release their viral inhibitory protein/s. 
 
 High levels of the co-stimulatory molecules, CD80 and CD86 that are usually only found on 
APC were found on the cells; however their expression is also reported in activated T cells. 
CD95 (TNFRSF6) adeath receptor, was also expressed at higher levels than the naïve cells. 
There was substantial expression of the chemokine receptors CD183 (CXCR3), 
CD184(CXCR4),CD196 (CXCR6),CD197 (CXCR7), whereas CD193 (CCR3), and CD195 
(CCR5), wereonly weakly expressed. The immunoregulatory molecules CD153, CD154, 
CD200R, CD69 as well as HLA-DR were expressed at higher levels than on primary T-cells 
as were the cytokine receptors CD122 and CD127. There was negligible staining for the 
homing receptors CD49d, CD62, CD103 and integrin ß7. The NK-cell marker (not in rhesus) 
CD56 is not expressed.The expression pattern of these surface markers was homogenous 
indicating that the cell line is either monoclonal or the transduction process lead to the same 
phenotype. Expression of all above mentioned markers suggest that cells somehow represent 
an unusual activated phenotype. Furthermore the cell line grows well in absence of IL-2 and 
thus has the characteristics of a transformed CD4+ Tcell line. This is the only rhesus macaque 
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T cell line available to date. It will be of high value for primate research, as it can replace the 
existing human T cell lines, e.g. used for propagation of SIV. Preliminary results indicate that 
this cell line is better infected with SIV strains (e.g. SIVagm) that otherwise poorly replicate 
on human T cell lines. 
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Summary and conclusion 
A small subset of HIV/SIV infected individuals can control viral replication, do not exhibit 
immunosuppression or disease for prolonged periods and are termed as long term non 
progressors (LTNP). One element of the protective responseto HIV-1 infection is the CD8+ T 
cell mediated noncytolytic antiviral response or CNAR. CNAR is associated with resistance 
to HIV infection among exposed seronegative individuals, long-term control of HIV-infection 
and reduced transmission of HIV. A lack ofmajor histocompatibility complex (MHC) 
restrictionand suppressionof HIV-1 replication in heterologousCD4+ cell targets distinguish 
this antiviral mechanismfrom the classical cytotoxic activity of CD8+ T cells. CNAR is 
reported to be mediated at least in part by production of a soluble CD8+ cell antiviral factor 
(CAF). To date no CD8+ cell-secreted cytokine, chemokine,or inflammatory molecule has 
been shown to identify with thehallmarks defining the HIV-1 transcription-suppressing 
activityof CD8+ T cells. To this end, our study focused on the discovery of novel genes and 
elucidation of their biological functions contributing to CNAR activity by using SIV-infected 
macaques as animal models. 
In order to identify the CNAR+ and CNAR- animals, in vitro viral inhibition tests were 
performed on both infected and non-infected animals. For the first time it was shown that 
CD8+ T cells of the non-infected animals (though to a lower extent than infected CNAR+) can 
display CNAR activity. In line with the previous studies animals that lacked CNAR activity 
had a higher viral load, and furthermore, loss of CNAR activity preceded the increase in viral 
load in two of the investigated animals. 
The gene expression profile of CD8+ cells with high CNAR activity and CD8+ cells that lack 
this antiviral activity were evaluated using microarray technology. Out of more than 50 
differentially regulated genes, expression of 16 genes was validated by qRT-PCR. FAM26F 
was identified as a sole candidate that was significantly differentially expressed in both 
infected as well as non-infected group of animals. Furthermore this increased FAM26F 
expression in CNAR- CD8+ T cells samples evolved during their co-cultivation with SIV-
infected CD4+ T cells during viral inhibition test (Fig 3.7B). FAM26F was found to be 
expressed on all three major cell populations (CD4, CD8+ T cells and B cells). In vitro 
stimulation studies revealed that FAM26F expression was greatly induced in PBMCs after 
6hrs of IFN-γ gamma stimulation, indicating that FAM26F could play an important role in 
diverse IFN-γ responses, both in innate and adaptive arms of immunity.  
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After finding FAM26F correlation with viral load in a small cross sectional study, the 
expression pattern of FAM26F before and after infection was investigated in two larger 
independent AIDS vaccine experiments. In both experiments, FAM26F expression increased 
after SIV-infection and followed same ex vivo expression pattern as Mx1, IP-10 and tetherin. 
FAM26F RNA levels were also found to be significantly correlated with Mx1, IP-10 and 
tetherin. All these observations emphasize that FAM26F could also be a possible candidate 
player in immune system, most probably of innate immunity. FAM26F in experiment 2 was 
inversely correlated with 2, 12 and 24 wpi viral load while in experiment- 1, 2wpi expression 
of FAM26F was found to be positively correlated with plasma viral RNA copies at 12, 24 and 
48 wpi. Both of these observations indicate that FAM26F may be an early predictor/indicator 
of viral load at set-point during the chronic phase of infection and can be considered as early 
prognostic marker for SIV/HIV infection. Further investigations using larger number of 
animals are required to validate these findings as well as samples from HIV-infected humans. 
 
Expression of FAM26F along with already defined surrogate innate immune markers (Mx1 
and IP-10) and a viral restriction factor (tetherin) was studied before immunization, 24 and 48 
h after final priming, after the boost and at the day of 1st challenge in two groups of animals. 
Group 1 was boosted with a fowlpox virus-derived vector whereas group 2 was boosted with 
adenovirus-derived vector. Expression levels of IP-10 (24hrs post boosting), FAM26F and 
tetherin (24 hrs and 48hrs post boosting) were significantly elevated in vaccinees of group 2 
as compared to group1.This difference was notable in the context that group 2 had lower viral 
load and increased level of protection as compared to group1.  
As the expression of Mx1 and tetherin is driven by IFN-α while those of IP-10 and FAM26F 
is induced by IFN-γ, we can extrapolate that both vectors elicited different immune responses 
that effected the viral outcome. The increased level of protection in group 2 can be attributed 
to more pronounced IFN-γ responses or a unique balance between type I and type II 
responses, which may have caused a differential activation of the innate cells and finally to 
differential adaptive immune responses.  
Although it is clear that FAM26F doesn’t fit to the criterion to be a candidate for CAF as its 
properties are different than the CAF (e.g. size and protease activity) and it is higher 
expressed in CNAR- than in CNAR+ animals, it is nevertheless possible that FAM26F acts 
somewhere intermediate in the mechanism of CAF inhibition. In summary, our in vitro 
stimulation as well as infection and immunization studies emphasize that FAM26F may be an 
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important regulator of innate or adaptive immune response. FAM26F expression may be an 
early indicator/marker of the immune status that is especially important during primary 
infection. This could mean that lower expression of FAM26F before infection may indicate an 
immune status that is able to limit early viral replication, whereas a strong increase after 
infection may indicate already early immune dysregulation that is later on associated with 
higher viral load. Thus FAM26F expression can be regarded an early diagnostic marker. 
Irrespective whether FAM26F is involved directly in regulation of viral replication or 
indirectly via the immune defense; our study has shown that it is an important molecule that 
clearly merits further investigation.  
Further result of the study was the establishment of a permanent CD4 T cell line. Further 
genetic and functional characterization of this cell line will be of great importance. This cell 
line will be a valuable tool for in primate basic as well as biomedical research.  
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Appendix 
APP Table 1: Table briefly summarizing the possible function/s of genes selected for 
validation. 
Gene  Brief summary of Functions  
CD26(DPP4) 
 
CD26 is an ecto-enzyme with help of its extracellular domain´s 
dipeptidyl-peptidase IV (DPP-IV) activity cleaves amino terminal 
dipeptides from polypeptides. On human T cells appears late in thymic 
differentiation and can deliver a potent co-stimulatory T-cell activation 
signal. Elicit signal transduction/ immunoregulatory mechanism via 
interaction with CD45 and adenosine deaminase (ADA), each of which 
is capable of functioning in a signal transduction pathway. It may be 
involved in cell migration and the HIV-1-associated loss of CD4+ cells 
through the process of programmed cell death.  
SLAMF8 It is member of the CD2 family of signaling lymphocytic activation 
molecule (SLAM), expressed in lymphoid tissues and characterized by 
Ig domains. SLAM-related receptors physically associate with SAP-
related adaptors and mediate stimulatory signals that promote immune 
cell activation or differentiation. In the absence of SAP-family adaptors, 
though, the SLAM family undergoes a "switch-of-function," to mediate 
inhibitory signals that suppress immune cell functions.  
GLUL The protein encoded by this gene belongs to the glutamine synthetase 
family. It catalyzes the synthesis of glutamine from glutamate and 
ammonia. Glutamine is a main source of energy and is involved in cell 
proliferation, inhibition of apoptosis, and cell signaling. This gene is 
expressed during early fetal stages, and plays an important role in 
controlling body pH by removing ammonia from circulation 
RPL13 The protein belongs to the L13E family of ribosomal proteins. It is 
located in the cytoplasm. This gene is expressed at significantly higher 
levels in benign breast lesions than in breast carcinomas. 
TNFSF 13B The protein encoded by this gene is a cytokine that belongs to the tumor 
necrosis factor (TNF) ligand family. It is a ligand for receptors 
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TNFRSF13B/TACI, TNFRSF17/BCMA, and TNFRSF13C/BAFFR. 
This cytokine is expressed in B cell lineage cells, and acts as a potent B 
cell activator. It has been also shown to play an important role in the 
proliferation and differentiation of B cells 
CST6 CST6 is typical secretory protease inhibitors. A candidate tumor 
suppressor gene for cancers of the breast, prostate, brain, lung, cervix 
and melanocytes.  
PSAT Encodes a phosphoserine aminotransferase which is involved in serine 
biosynthesis in the chloroplast which operates via the phosphorylated 
pathway. 
CHYMASE-1 This gene product is a chymotryptic serine proteinase that belongs to the 
peptidase family S1. It is involved in the degradation of the extracellular 
matrix, the regulation of submucosal gland secretion, and the generation 
of vasoactive peptides 
GSTO-1 The protein encoded by this gene is an omega class glutathione S-
transferase (GST) with glutathione dependent thiol transferase and 
dehydroascorbate reductase activities. 
PRSSL-1 Also called (kallikrein-related peptidase 10KLK10) in human. 
Kallikreins are a subgroup of serine proteases having diverse 
physiological functions. Growing evidence suggests that many 
kallikreins are implicated in carcinogenesis and some have potential as 
novel cancer and other disease biomarkers 
FAM26F Member F of the family with sequence homology 26 . It is involved in 
dendritic cell mediated activation of NK cells.  
PON-3 This gene is a member of the paraoxonase family and lies in a cluster on 
chromosome 7 with the other two family members. The encoded protein 
is secreted into the bloodstream and associates with high-density 
lipoprotein (HDL). The protein also rapidly hydrolyzes lactones and can 
inhibit the oxidation of low-density lipoprotein (LDL), 
LOCUS(Galanin) Galanin is small neuropeptide that functions as a cellular messenger 
within the central and peripheral nervous systems, modulating diverse 
physiologic functions 
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MMP25 Proteins of the matrix metalloproteinase (MMP) family are involved in 
the breakdown of extracellular matrix in normal physiological processes, 
such as embryonic development, reproduction, and tissue remodeling, as 
well as in disease processes, such as arthritis and metastasis 
EPHB This gene belongs to the ephrin receptor subfamily of the protein-
tyrosine kinase family. implicated in mediating developmental events, 
particularly in the nervous system This gene is expressed in some human 
cancer cell lines and has been implicated in carcinogenesis 
CISH 
 
The protein thus belongs to the cytokine-induced STAT inhibitor (CIS). 
CIS family members are known to be cytokine-inducible negative 
regulators of cytokine signaling. The expression of this gene can be 
induced by IL2, IL3, GM-CSF and EPO in hematopoietic cells 
 
 
APP Table 2: Table depicting accession number of the genes validated by qRT PCR along 
with primer sequences used for amplification on along with amplicon lengths. 
 


Gene  Accession Number  Primer Sequence (5` to 3`) 
Product Size  
(bp) 
 GAPDH  
 
CO774281 
F CCT GCA CCA CCA ACT GCT TA 
74 
R CAT GAG TCC TTC CAC GAT ACC 
A 
Mx1 
 
EF101561 
F AGG AGT TGC CCT TCC CAG A 
76 
R TCG TTC ACA AGT TTC TTC AGT 
TTC A 
IP10,CXCL10  
 
AY044446 
F GAT TTG CTG CCT TGT CTT TCT 
GA 
74 
R CAG GTA CAG CGT ACA GTT CTT GAG A 
CD26(DPP4) DQ324530 
F CAA ATT GAA GCA GCC AGA CA 
108 
R TCC CAG GAC CAT TGA GGT TA 
SLAMF8 XM_001117299.2 
F GCA GAT CCA CAC TGC TCA AA 
110 
R ATT GGT CTC ACG GAA GCA CT 
GLUL XM_001114930.2 
F CCG GAT TAG AAA CCA AGC AT 
107 
R GCA GAA ACC CAG AAG TGG TC 
RPL13 XM_002802597.1 
F CAA AGC CTT CGC TAG TCT CC 
98 
R TTT CAA CAT CCT GTT CTG CG 
TNFSF 13B XM_001082247.2 
F GCG ATA AGTG GAG TCA GAG 
TTT C 105 
R GCA AAA GGC AAT GAA GGT TT 
CST6 XM_001111664.2 
F TAC AAC ATG GGC AGC AAC AG 
100 
R CCA TCT CCA TCG TCA GGA A 
PSAT XM_001101767.2 
F CCT GCT TAT TTT GCC TTT GC 
108 
R TGT GTT CCC ATG ACT CCA GA 
CHYMASE-1 AANU01225520.1 
F CAC AGA ATG CAA GCC ACA CT 
104 
R TGT CAG CAC AAA GTT CCG TC 
GSTO-1 XM_001099994.2 
F GGC TGG AAG CAA TGA GGT TA 
95 
R GGC TGA GAC TGT GGG ATC TT 
PRSSL-1 XM_001117143.2 
F CTG ACT TTG AGG ATC TGC CG 
104 
R CAT CGT ATG GCT CAG GTG G 
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FAM26F XM_001111520.2 
F TGT TGG GCT GGA TCT TGA TAG 
98 
R CTG CTG CTT CCT GTT CCA A 
PON-3 NM_000940.2 
F ACT TCC TAG TGG GCT GGC TT 107 
R GTT ACT TCA GAT CCA TCA AG 
LOCUS(Galanin) XR_091573.1 
F CCA TGC CTG AGA ACA ATA 
TCA 130 
R GAC CGC TCC ATG TCT TCT 
MMP25 XM_001091146.2 
F CGG ACC TGT TTG CCG TGG CT 
117 
R TGT CAG GGT TGC CCA CCG GA 
EPHB1 XM_001115263.2 
F CGG CGA GAG CGC GAA AGG AT 100 
R GAG CCC GAG CTG AGG CAG CA 
CISH 
 
XM_001097824.2 
F GGA TGT GGT CAG CCT TGT 
110 
R CAG GCA GTG CTG GAT CAT TA 
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